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ABSTRACT OF DISSERTATION 
 
 
 
IDENTIFICATION OF SUMOYLATED PROTEINS AND INVESTIGATION OF 
PROTEIN UBIQUITINATION IN THE NF-κB PATHWAY 
 
SUMOylation and ubiquitination are important post-translational modifications. 
While ubiquitination is well known for targeting proteins for degradation, SUMOylation 
often regulates the intracellular localization of substrates. In the first project of this 
dissertation, we developed proteomic strategies to identify novel SUMOylated proteins in 
mammalian cells. In the second project, we investigated the regulation of protein 
ubiquitination in the NF-κB signaling pathway in the context of Paget’s disease of bone 
(PDB).  
Identification of SUMOylated proteins has been a challenge because of low 
abundance of SUMOylation substrates. Here, we utilized a mass spectrometry (MS)-
based proteomic approach to identify novel SUMOylated proteins in mammalian cells. 
Seventy-four unique proteins were commonly identified in the collection of four SUMO-
1 plasmids, thus considered candidate SUMOylated proteins. Many of these proteins are 
associated with the nucleus. The results were validated by confirming SUMOylation of a 
novel substrate Drebrin and a well known substrate Ran-GAP1. Furthermore, the 
potential SUMOylation sites in Drebrin have been identified and confirmed using site-
directed mutagenesis.  
PDB is a disorder characterized by increased bone turnover containing 
hyperactive osteoclasts. Mutations in Sequestosome 1 (p62) are associated with 40% of 
familial PDB. P62 is a scaffold protein and plays a critical role in regulating 
ubiquitination of TRAF family signaling molecules and mediating the activation of NF-
κB by RANK and TNFα ligands. P62 also plays a critical role in shuttling substrates for 
autophagic degradation. The objective of this project is to determine the effects of PDB-
associated p62 mutants on NF-κB signaling and autophagy. We compared the effect of 
wild-type (WT) p62 and PDB mutations (A381V, M404V and P392L) on the TNFα-
induced NF-κB signaling using an NF-κB luciferase assay. Our results show that these 
p62 mutations increased the NF-κB signaling. In addition, we found that the PDB 
mutations did not change the interaction between p62 and the autophagy marker protein 
LC3. In summary, the PDB mutations in p62 are likely gain-of-function mutations that  
 
 
can increase NF-κB signaling and potentially contribute to disease progression. Based on 
the results, we proposed a model to speculate the synergetic role of p62 PDB mutant on 
NF-κB signaling and autophagy.  
KEYWORDS: SUMOylation; ubiquitination; Paget’s disease of bone (PDB); p62; NF-
κB signaling  
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1 
Chapter 1. Background and introduction 
 
Dissertation overview 
 
SUMOylation and ubiquitination are two important post-translational 
modifications [1, 2]. This dissertation consists of two parts. In the first part (Chapter 2), 
we developed a relatively simple proteomic method to identify SUMOylated proteins in 
mammalian cells. We are also the first group to identify and validate that an actin-binding 
protein, Drebrin [3], could be SUMOylated. The second part (Chapter 3 and 4) of this 
dissertation is related to “ubiquitination” for the following reasons. Firstly, p62 is an 
ubiquitin-binding protein [4-6]. Secondly, most of the PDB-associated p62 mutations are 
in the ubiquitin-associated (UBA) domain [7]. Thirdly, in Chapter 3, we proposed that 
p62 PDB mutants increase the NF-κB signaling through increasing TRAF6 
polyubiquitination. Fourthly, in Chapter 4, we studied the effect of p62 PDB mutants in 
autophagy. Autophagy is involved in degradation of polyubiquitinated proteins [8]. 
Currently, little is known about cellular consequences of  PDB-associated p62 
mutants currently [9]. To fill in this gap, we focused on studying the cellular 
consequences of PDB-associated p62 mutants on the NF-κB signaling and autophagy.  
We found that p62 PDB mutants increased TNFα-induced NF-κB signaling, but not 
through TRAF6 polyubiquitination (Chapter 3). Additionally, we showed that PDB 
mutants did not change the interaction between p62 and the autophagy marker protein 
LC3 (Chapter 4). Finally, an integrated model for the role of PDB mutant p62 in NF-κB 
signaling and autophagy is proposed (Fig. 5.1). 
 
 
2 
 
SUMOylation 
 
Discovery of SUMO 
The small ubiquitin-like protein modifier (SUMO) was firstly discovered as 
reversible post-translational modification by several groups in the middle 1990s [10-12]. 
The first SUMOylated protein identified is Ran-GTPase-activating protein 1 (Ran-GAP1), 
which had been implicated in both nuclear transport and the control of mitosis [11, 12]. 
In 1997, the researchers found that cells contain two forms of RanGAP1, 70 kDa and 90 
kDa [11]. Further analysis showed that the larger form contained  a 97 amino acid protein, 
which is similar to ubiquitin in its shape,  known as SUMO [12, 13]. 
Generally, three major SUMO paralogues, SUMO-1, SUMO-2 and SUMO-3 are 
expressed in cells [14]. It is not certain whether SUMO-4 protein is expressed in cells 
although a gene encoding SUMO-4 has been reported [15]. SUMO-2 and SUMO-3 are 
often referred to as SUMO-2/3 because they share 98% sequence similarity. However, 
SUMO-2/3 and SUMO-1 have only approximately 50% sequence identity [10, 16]. 
Human small ubiquitin-like modifier 1 (hSUMO-1) is a protein of 101 amino acids,  
similar to ubiquitin in 3D structure, even though they only share 17% homology at the 
amino acid level [17-19]. The SUMO-1 precursor has to be cleaved by SUMO-specific 
proteases to expose a C-terminal glycine-glycine (GG) functional group for subsequent 
SUMO activation and conjugation [1]. 
SUMOylation often regulates protein intracellular localization, protein-protein 
interactions or transcription regulator activity [2, 20]. SUMOylation is essential to normal 
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cellular behavior. Dysregulation of protein SUMOylation has been associated with a 
number of diseases such as cancer, neurodegenerative disease, viral infection, diabetes 
and developmental defects [2]. 
SUMOylation vs. ubiquitination 
SUMOylation and ubiquitination are two important post-translational 
modifications in the cells. They share many similarities but they are also different in 
many aspects [21]. 
(1) Similarity 
SUMO and ubiquitin have similar protein size, tertiary structure and a C-terminal 
di-glycine motif. Both SUMO and ubiquitin target the protein with the help of E1 
(activating enzyme), E2 (conjugating enzyme) and E3 ligases. In addition, both SUMO 
and ubiquitin proteins are synthesized as immature precursors. These precursors are 
processed by the specific hydrolase for subsequent activation and conjugation [14, 22]. 
(2) Difference 
Ubiquitination is well known for targeting substrates for degradation, whereas 
SUMOylation regulates a substrate’s functions mainly by altering the intracellular 
localization, protein-protein interaction and transcription factor activity. In addition, the 
ubiquitin pathway has a large number of E2 s and E3 s, whereas the SUMO pathway only 
uses a single E2 and a few E3 s [17]. 
 
SUMO conjugation, deSUMOylation and SUMO consensus sequence 
 
 
4 
It is well known that ubiquitin conjugation requires E1 ubiquitin-activating 
enzyme, E2 ubiquitin-conjugating enzyme and E3 ubiquitin ligase [23]. SUMO 
conjugation is very similar to ubiquitin conjugation (Fig. 1.1). SUMO proteins are 
synthesized as inactive precursors, which must first undergo a C-terminal cleavage 
mediated by a family of sentrin/SUMO-specific protease (SENP) enzymes. This cleavage 
exposes a di-glycine motif, which is available for subsequent activation and conjugation 
[14]. In each conjugation cycle, SUMO is activated in an ATP-dependent manner by the 
E1 “activating” enzyme. SUMO is then passed to the active site of the conjugating 
enzyme Ubc9 (ubiquitin-conjugating 9). Finally, SUMO is covalently attached to lysine 
residues of the target protein through the isopeptide bond between the terminal glycine 
residue and the ε-amino group of a lysine residue in the target protein by SUMO E3 
ligase [1, 24, 25]. SUMOylation is a highly dynamic process that can be reversed by 
deconjugating enzymes such as the SENP enzymes [26] 
The SUMO-1 consensus sequence is a motif of conserved residues next to the 
modified lysine residue and is found in many identified SUMO-1 substrates [27]. The 
sequence is ΨKXE/D, where Ψ is a large hydrophobic residue (such as Val, Ile, Leu, Met, 
or Phe). K is the lysine to which SUMO-1 is conjugated and X is any amino acid, D is 
aspartic acid and E is glutamic acid. More than two-thirds of the known substrate proteins 
have at least one SUMOylation consensus sequence ΨKXE/D [2, 28]. However, 
SUMOylation can also occur at lysine residues without this consensus motif, such as non-
consensus SUMOylation sites. In addition, although not all lysine residues within the 
ΨKXE/D motif are SUMOylated [1], SUMOylation consensus sequence ΨKXE/D is still 
generally believed to be helpful for predicting SUMOylation sites. 
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Classification of SUMOylation substrates 
To date,  more than 120 mammalian substrate proteins for SUMOylation have 
been identified [2]. Based on the subcellular localization of identified SUMOylation 
substrates, they could be classified as nuclear proteins, cytoplasmic proteins and trans-
membrane proteins. The majority of these substrates are nuclear proteins, indicating that 
SUMOylation is primarily involved in nuclear functions. However, a growing number of 
non-nuclear proteins have been identified, suggesting important non-nuclear roles of 
SUMOylation [29-31]. 
The nuclear SUMOylation substrates are well studied. These substrates could be 
further classified into nuclear pore complexes, transcription factors and coregulators, 
DNA replication and repair proteins, as well as kinetochore and  centromere proteins [2, 
32-34]. Functions of SUMOylation of these nuclear proteins are summarized in the Fig. 
1.2. 
A growing number of non-nuclear SUMOylation substrates have been identified, 
indicating more functions of SUMOylation beyond those related to the nucleus [2]. Ran-
GAP1, the first identified SUMOylation substrate is a cytoplasmic protein. SUMOylation 
is clearly required for targeting Ran-GAP1 to the nuclear pore complex (NPC) [11]. Also, 
some identified SUMOylation substrates are transmembrane proteins, such as death 
receptors, Fas and TNFR1. SUMOylation of these receptors inhibits their apoptotic 
signaling [2, 35]. It is noted that a number of non-nuclear SUMOylation substrates are 
involved in signal transduction. SUMOylation of these proteins could change the activity, 
stability, or subcellular distribution of the proteins and eventually alter signaling events. 
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For example, SUMOylation protects inhibitor of NF-κB (IκB) from ubiquitination and 
degradation by 26S proteasome [2, 30]. 
 
Functional consequences of SUMOylation 
The major functional consequences of SUMOylation include alteration of protein 
localization, protein-protein interactions and transcription regulator activity [2, 36]. 
(1) Protein localization 
As mentioned earlier, Ran-GAP1 is a cytosolic protein.  Only SUMOylated Ran-
GAP1 binds Ran-GTP binding protein (RanBP2), which mediates SUMOylated Ran-
GAP1 translocation from the cytosol to the nuclear pore [11, 37]. Therefore, 
SUMOylation is critical for nuclear import of some proteins. In addition, SUMOylation 
could also target substrate proteins to specific locations within the cytoplasm. For 
example, DRP1 is a GTPase protein required for mitochondrial fission. SUMOylation of 
DRP1 facilitates its recruitment from the cytosol to the mitochondrial outer membrane 
[38]. 
(2) Protein-protein interactions 
SUMOylation of Ran-GAP1 is also an example of SUMOylation being involved 
in protein-protein interactions. As discussed earlier, only SUMOylated Ran-GAP1 can 
bind RanBP2. It is hypothesized that SUMO may serve as an interaction “hub” that 
recruits new interacting proteins to the substrate [1, 2]. For another example, it has been 
demonstrated that SUMOylation of transcription factor Elk1 could recruit the histone 
deacetylase 2 (HDAC2). This recruitment has been shown to result in decreased histone 
acetylation of Elk-1-regulated promoters and thus transcriptional repression of Elk-1 
target genes [39]. 
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(3) Transcription regulator activity 
Most SUMOylation substrates are nuclear proteins. Particularly, the primary 
nuclear SUMOylation substrates are transcription factors and regulators. In most cases, 
SUMOylation negatively regulates gene expression by either enhancing the function of 
transcription repressors or inhibiting the function of transcription activators [34, 40, 41]. 
However, the opposite occurs occasionally. For example, heat shock factor 1 (HSF1) is 
SUMOylated in response to stress and HSF1 SUMOylation often leads to activation of its 
target genes [13, 42]. 
 
SUMOylation and disease 
As described above, SUMOylation is a dynamic process that could be reversed by 
deconjugating enzymes such as the SENP enzymes [1, 26]. A delicate balance between 
SUMOylation and deSUMOylation is essential to normal cell functions (Fig. 1.2). 
Growing evidence has shown that the loss of this balance in SUMOylation and 
deSUMOylation can lead to diseases including cancer, diabetes and neurodegenerative 
diseases such as Alzeimer’s  disease, Parkinson’s disease, familial amyotrophic sclerosis 
(fALS) and Huntington’s disease [2, 14, 43]. For example, a recent study has shown that 
SUMOylation of amyloid precursor protein (APP) close to the β-secretase cleavage site is 
associated with a decrease of Aβ aggregates, which is generally believed a probable cause 
of Alzeimer’s disease [14, 29, 31]. The causative relationships between the deregulation 
of SUMOylation and pathogeneses of the diseases are still unclear and under active 
investigation. Studies so far have suggested that SUMO target proteins might be 
therapeutic targets for treating these diseases [14, 43]. 
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In our study, we used a modified proteomic method to identify SUMOylated 
proteins in HEK293 cells. We also found that Drebrin is a novel substrate for 
SUMOylation. Background about Drebrin is described as below.  
 
 
Discovery, isoforms and domains of Drebrin 
Developmentally-regulated brain protein (Drebrin) is an actin-binding protein, 
involved in the regulation of actin filament organization. Drebrin plays an important role 
during the formation of neurites and cell protrusions of motile cells [44]. The expression 
level of Drebrin is very high in the cerebral cortex, hippocampus, thalamus and striatum 
[45]. Drebrin was originally discovered by Shirao et al. [46]. 
Drebrin has three isoforms  including E1, E2 (embryonic) and A (adult) isoform, 
which are generated by alternative RNA splicing from a single Drebrin gene [47]. 
Drebrin E1 and E2 were first identified as developmentally regulated brain proteins by 
two-dimensional gel electrophoresis in 1985 [46]. Drebrin A was discovered using a 
monoclonal antibody against Drebrin E in 1986 [48]. A cDNA clone for a common 
domain of Drebrin E1, E2 and A was first isolated from brains of 10-day chick embryos 
in 1988 [3, 49].  All three isoforms are strongly expressed in neurons [44]. On SDS-
PAGE gels, the molecular weight of Drebrin A is about 125 kDa and the molecular 
weight of Drebrin E is about 115 kDa [45]. 
The N-terminal domain of Drebrin is an actin-depolymerizing factor homology 
(ADF-H) domain which is highly conserved across vertebrate [50]. Also, there is an 
actin-binding domain close to ADF-H. In the C terminus of Drebrin, there are homer-
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binding motifs [44]. Homer proteins are scaffold proteins at the post-synaptic density 
where they facilitate synaptic signaling and appear to be critical in learning and memory 
[51]. 
 
 
Drebrin contributes to the formation of filopodia 
The formation and maintenance of an appropriate shape is fundamental to cells. It 
is also important for cells to modulate morphology in response to changing 
environmental stimuli. The cytoskeleton plays an important role to provide both a rigid 
scaffold and mechanical forces to move the cell [44]. Also, the cytoskeleton is regulated 
by many proteins which bind cytoskeletal components such as microtubules and actin 
filaments. Drebrin is one of these actin-binding protein [44], and growing evidence shows 
that Drebrin is important for controlling cell shape and function by its interaction with 
other proteins [44]. 
The most visualized function of Drebrin is that Drebrin contributes to filopodia 
formation in neurons and other cell types [52]. In 1992, it was firstly reported that 
exogenous GFP-Drebrin A accumulated within spines and elongated the length of spine 
[53-55]. Later, it was reported that overexpression of full length Drebrin, or truncations 
containing the actin-binding domain, induced the formation of numerous microspikes in 
fibroblasts and massive spines in cultured hippocampal neurons [44, 56, 57]. Also, it was 
shown that overexpression of Drebrin E2 in cultured epithelial cells resulted in a 
phenotype similar to that produced in neurons and fibroblasts [44, 58].  It was also shown 
that filopodia formation could also be inhibited by a reduced amount of Drebrin [52]. 
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In our study, we used the proteomic method to first show that Drebrin could be 
SUMOylated. Additionally, we found the potential SUMOylation sites of Drebrin. We 
also try to investigate the functional consequence of Drebrin SUMOylation. 
Next, we will talk about another post-translational modification, ubiquitination, 
which is similar with SUMOylation described above. Here, we firstly will introduce a 
disease called Paget’s disease of bone (PDB) because mutation in the gene encoding an 
ubiquitin-binding protein, p62 is associated with PDB. Then, we will describe the protein 
p62 in detail. We also will introduce NF-κB signaling, in which ubiquitination of many 
proteins occur.  In the end, we will describe autophagy, which is involved in degradation 
of polyubiquitinated proteins [8]. 
Paget’s disease of bone (PDB) 
 
Prevalence and symptoms of PDB 
Paget’s disease of bone is named after Sir James Paget who was a British Surgeon.  
In 1876, he published a scientific article describing cases of previously unrecognized 
chronic bone disease, which he called “osteitis deformans”. Over 120 years after Sir 
Paget’s finding, scientists and clinicians began to make significant progress in 
understanding the etiology of the condition we now know as Paget’s disease of bone 
(PDB) [59], which is the second most common bone disease after osteoporosis [60]. 
PDB is most common in England, Western Europe, and North America. Very few 
cases have been reported in Asia and Africa [59]. Approximately 3% of individuals aged 
over 50 years are affected with PDB in Caucasian populations [7, 61].  PDB is not lethal, 
but a chronic disorder that typically results in deformed bones [9]. The symptoms include 
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bone pain, susceptibility to pathological fractures, osteoarthritis, headache, deafness and 
neurological complications [59, 62, 63]. Osteosarcoma often occurs in PDB patients [64]. 
An elevated level of alkaline phosphatase, bone scans, x-rays help the diagnosis [61]. 
Currently, the common drug for treating the PDB are bisphosphonates, a class of 
relatively non-selective compounds that target and induce apoptosis of osteoclasts [7].  
 
 
PDB is a disorder of bone remodeling 
 
Bone mass in human being is controlled by both osteoclasts (bone-resorbing cells) 
and osteoblasts (bone-forming cells) [65]. The opposing activities of these two cell types 
ensure that bone is constantly remodeled in a process essential to maintain adult bone 
structure and function [59]. 
PDB is characterized by focal areas of increased bone turnover containing 
enlarged hyperactive osteoclasts [7, 66]. Pagetic lesions contain increased numbers of 
osteoclasts compared with normal bone, which have increased size and contain more 
nuclei than normal osteoclasts [7]. The increased osteoclast activity leads subsequently to 
increases in osteoblast activity [59]. Although bone resorption (osteoclast) initially 
exceeds formation (osteoblast), bone formation greatly exceeds bone resorption in later 
stages. Therefore, the overall process of bone formation becomes accelerated and 
disorganized, ultimately resulting in abnormal bone structure. 
 
RANK plays an important role in the formation of osteoclast 
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Receptor activator of nuclear factor kappa-B ligand (RANKL), also known as 
TNF-related activation-induced cytokine (TRANCE) or osteoprotegerin ligand (OPGL), 
is a member of the tumor necrosis factor superfamily.  It is most abundantly expressed as 
a cell surface protein by bone marrow stromal cells [67-69]. In 1998, RANKL (OPGL) 
was shown to be the main osteoclastogenic cytokine both in vitro and in vivo [67, 70, 71]. 
Osteoclast precursors are monocyte/macrophages. It was reported that RANKL 
could transform the macrophages to osteoclasts [67, 70, 71]. RANKL could interact with 
its receptor RANK (Fig. 1.5) [72]. RANKL and RANK are encoded by Tnfsf11 and 
Tnfrsf11a genes, respectively [67].  It has been reported that both Tnfsf11-knockout mice 
(without RANKL) and mice in which Tnfrsf11a has been deleted (RANK–/–) fail to 
generate osteoclasts [67, 71, 73]. However, Tnfrsf11a knockout mice (RANK –/–) could 
be rescued by RANK-expressing haematopoietic cells, which suggests that RANK plays 
an important role in osteoclast formation [67, 73]. 
 
Etiology of PDB: disordered RANKL-induced NF-κB signaling 
It has been generally accepted that disordered osteoclast RANKL-induced NF-κB 
signaling may be central to disease etiology [9].  RANKL-induced NF-κB signaling plays 
a role in regulating the transformation of osteoclast to activated osteoclast [67].  
Therefore, hyperactivated osteoclasts identified in PDB patient might be due to the up-
regulation of RANKL-induced NF-κB signaling [9]. 
There are other factors that also contribute to PDB. It is suggested that PDB 
etiology is also involved with slow virus [59]. It has been shown that the infection of 
osteoclasts with a paramyxovirus is a possible cause of PDB [74]. Exposure to 
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environmental toxin could be another factor affecting PDB incidence. PDB cases in 
Lancashire (county of historic origin in the North West of England) identified in a 1974 
survey have been linked to the cotton industry. It was proposed that arsenic pesticide 
from cotton bales might be responsible for the high prevalence of disease [75]. 
Both viral infection and exposure to environmental toxins such as arsenic may 
upregulate the expression of SQSTM1 (p62), which is an important protein in RANKL-
induced NF-κB signaling pathway [7, 9, 59]. 
 
Genetics of PDB: p62 (SQSTM1) mutations 
The most common genetic mutations found in classical PDB patients are in the 
SQSTM1 (sequestosome1) gene, located on chromosome 5 at the PDB3 locus [59, 76].  
This gene encodes the SQSTM1 protein (also known as p62), which has diverse 
functional properties [59, 76]. In osteoclasts, p62 appears to be an important component 
in the RANKL-induced NF-κB signaling pathway [59, 77].  Mutations in p62 gene are a 
major cause of PDB, but do not account for all cases of PDB [7].  Mutations in p62 gene 
have also been associated with familial and sporadic disease in up to 40% of cases [7]. 
To date, over 20 PDB-associated p62 mutations have been identified. Most of the 
p62 PDB mutations are either missense or truncating mutations in the ubiquitin-
associated (UBA) domain, the C terminus of the p62 protein.  A few p62 PDB mutations 
are outside of UBA domain [9]. 
Recent studies have supported the idea that p62 PDB mutations including P392L, 
P384S and K378X, are associated with increased RANKL-induced NF-κB signaling 
compared with wild-type p62 [9, 78-81]. While p62 mutations are linked to most cases of 
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PDB, mutations in genes encoding other proteins including VCP and RANK, are linked 
to PDB- related syndromes [59]. 
In our study, we are interested in cellular consequences of PDB-associated p62 
mutations. Thus, we investigated the impact of these p62 mutations on NF-κB signaling 
and autophagy. 
 
 
P62 (Sequestosome 1) 
 
The domain structures of p62 
P62 is also called sequestosome 1 or SQSTM1 [82]. It is a conserved 
multifunctional protein that is mainly involved in cellular signaling, protein degradation, 
protein aggregation and apoptosis [5, 83-85]. Plus, p62 is a cellular protein which is 
found in almost all mammalian cell types [86]. It was identified as a common component 
of cytoplasmic inclusions in protein aggregation diseases including amyotrophic lateral 
sclerosis (ALS) [87] and other neurodegenerative diseases [88]. 
The p62 gene has 8 exons and encodes a protein of 440 amino acids [89]. The 
diverse functions of p62 could be reflected by its domain structure (Fig. 1.4 A) [90]. 
Generally, p62 consists of six domains/motifs: Phox and Bem1 (PB1) domain, ZZ-type 
zinc finger, the SOD1 mutant interaction region (SMIR), TRAF6 binding (TB) motif, the 
microtubule-associated protein 1 light chain 3B (LC3) interaction region (LIR) and an 
ubiquitin binding-associated (UBA) domain [5, 83]. 
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(1) PB1 domain 
The N-terminal Phox and Bem1 (PB1) domains of p62 could form heterodimers 
with other PB1 domains, and could also form homodimers and homooligomers of p62 
[83, 91, 92].  The PB1 domain of p62 interacts with the PB1 domain of a number of 
proteins including atypical protein kinase C (aPKC), MAPK/ERK kinase 5 (MEK5), 
extracellular responsive kinase (ERK) and neighbor of BRCA1 gene 1 (NBR1). 
Particularly, the interaction of p62 and aPKC plays an important role in NF-κB signaling 
described below [5]. 
(2) ZZ-type zinc finger 
The ZZ-type zinc finger mediates the interaction of p62 with receptor-interacting 
protein kinase 1 (also called RIP, RIP1 or RIPK1) [83, 93]. This interaction also plays an 
important role in the TNFα-induced NF-κB signaling pathway. 
(3)SMIR motif 
We identified a motif that is essential for the interaction of p62 with mutants of 
the Cu/Zn superoxide dismutase (SOD1) linked to familial ALS [83]. The SOD1 mutant 
interaction region (SMIR, residues 178-224) is the actual sequence that interacts with 
mutant SOD1. In particular, the conserved W184, H190 and the positively charged R183, 
R186, K187 and K189 residues within the SMIR are critical for the interaction because 
substitution of these residues with alanine significantly impaired the p62-mutant SOD1 
interaction. In addition, oligomerization of p62 via the PB1 domain also plays an 
indispensable role in the p62-mutant SOD1 interaction [83]. The ubiquitin-independent 
recognition of misfolded proteins by SMIR is illustrated in Figure 2. 
(4) TB motif 
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P62 binds to the TNF receptor-associated factor 6 (TRAF6) through the TRAF6 
binding (TB) motif. TRAF6 is an E3 ubiquitin ligase in the RANKL-induced NF-κB 
signaling pathway. The interaction of p62 with TRAF6 could promote K63 linked 
polyubiquitination of TRAF6, which could further activate NF-κB [5]. The interaction of 
p62 with the E3 ubiquitin ligase TRAF6 promotes K63-linked polyubiquitination of 
TRAF6 and of other substrates such as Trk A and IKKγ [94-96]. 
(5) LC3 interaction region (LIR) 
The microtubule-associated protein 1 light chain 3B (LC3) is a protein essential to 
autophagosome formation [83, 97]. The LC3 interaction region (LIR) of p62 can directly 
interact with LC3 [83, 97]. Particularly, one PDB-associated p62 mutation, D335E, is 
found in this LIR region [98]. 
(6) Ubiquitin binding-associated (UBA) domain 
The C-terminus of ubiquitin binding-associated (UBA) domain of p62 is 
responsible for ubiquitin binding [82, 99, 100]. It is proposed that p62 interacts with 
polyubiquitinated proteins through the UBA domain. Once the polyubiquitin chain of a 
substrate protein binds to the UBA domain of p62, the substrate can be either translocated 
to the proteasome or autophagosome for degradation (see below). 
The role of p62 in protein degradation 
P62 plays a critical role in both ubiquitin-proteasome system (UPS) and 
autophagy, the two major known protein degradation pathways in mammalian cells (Fig. 
1.6). P62 was reported to be a shuttling factor to the proteasome [4, 82, 101]. 
Accumulating evidence suggests that the involvement of p62 in autophagy is likely more 
important. Moreover, p62 can mediate the cross-talk between the UPS and autophagy. It 
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was proposed that p62 accumulation after autophagy inhibition could further suppress the 
clearance of ubiquitinated proteins destined for proteasomal degradation [102]. 
The p62 protein plays a critical role in autophagy as a cargo receptor. P62 is 
frequently detected in protein inclusions related to human diseases [88, 103-105]. The 
depletion of p62 inhibited autophagic degradation of aggregation-prone polyglutamine-
expanded huntingtin inclusions while p62 protected cells from cell death induced by 
polyglutamine-expanded huntingtin [89]. Inhibition of autophagy caused elevated levels 
of p62 and induced more and larger p62 inclusions [89, 106, 107]. It was found that p62 
actually regulates the formation and autophagic removal of protein inclusions [89, 106]. 
p62 binds directly to LC3 through its “LC3 interaction region” (LIR) [89, 97] that is 
critical to its ability to shuttle substrates to autophagosomes for degradation [97, 108, 
109]. The C-terminal UBA domain can interact with polyubiquitin chains [100]. It was 
proposed that p62 targets ubiquitinated protein aggregates to autophagy through an 
interaction between its UBA domain and polyubiquitin [97]. However, our lab found that 
the UBA domain of p62 was dispensable for the recognition of familial ALS-related 
mutant SOD1 [83]. Instead, an internal sequence motif, the SMIR plays a critical role in 
mutant SOD1 recognition, suggesting that p62 might also target protein cargos for 
autophagic degradation via ubiquitin-independent mechanisms [83]. 
 
PDB-associated p62 mutations and phenotype 
The most common genetic mutations found in classical PDB patients are in the 
p62  gene, located on chromosome 5 at the PDB3 locus [59, 76]. To date, over 20 PDB-
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associated p62 mutations have been identified [9]. Most of the p62 PDB mutations are in 
the UBA domain [110]. A few p62 PDB mutations are outside of UBA domain [9].  
 
(1) p62 UBA domain mutations 
In 2003, the three-dimensional structure of the p62 UBA domain (residues 387-
436) was determined by protein NMR (Fig. 1.4 B) [99, 111]. Identified p62 UBA domain 
mutations include P387L [112], P392L [113, 114], L394X [115], E396X [112], S399P 
[116], M404V [115, 117], G411S [115], G425R [115, 117], M404T [116] and others. 
Moreover, it was demonstrated that all of these mutations impaired K48-linked 
polyubiquitin binding by p62 in vitro [116]. Therefore, it was proposed that the disease 
mechanism in PDB involves a common loss of ubiquitin binding of p62. Interestingly, 
the mutations found in the UBA domain, P392L, G411S and G425R were also recently 
reported in ALS patients [118]. These findings suggest that p62 mutations might 
represent a causative or risk factor in ALS too. 
 
(2) p62 non-UBA domain mutations 
In recent years, more PDB-associated p62 mutations have been found in the non-
UBA domain. A D335E missense mutation located in the LC3-intearcting region (LIR) 
of p62,  50 amino acids away from UBA domain was identified [9]. Other non-UBA 
mutations include P364S [79], A381V [78, 98], Y383X [98] and others. 
In our study, we mainly investigated the effect of PDB-associated p62 mutations 
on NF-κB signaling and possible mechanisms. We selected three p62 UBA domain 
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mutations (P392L, M404V and G411S) and two p62 non-UBA domain mutations 
(D335E and A381V) in our work. 
 
NF-κB signaling 
Nuclear factor κB (NF-κB) is a transcription factor found in almost all 
mammalian cell types [119, 120]. NF-κB is well known for regulation of immune 
responses and inflammation [119, 121]. Growing studies have shown that NF-κB is also 
involved in the oncogenesis [121], bone diseases [65] and cell death [122]. 
Currently, the numerous studies of NF-κB consist of website  (www.nf-kb.org), 
patent and around 25,000 publications [120]. Here, we only focus on introducing 
RANKL-induced and TNFα-induced NF-κB signaling pathways which are related to our 
research topic. 
RANKL-induced NF-κB signaling 
RANKL is a cytokine that is highly expressed in bone marrow [67]. RANKL-
induced NF-κB activity controls normal osteoclastogenesis and also plays an important 
role in the bone resorbing function of mature osteoclasts [59, 67, 123]. Therefore, 
upregulation of RANKL-induced NF-κB signaling could at least in part explain the 
increase in osteoclastic activity in PDB [59]. 
The binding of RANKL and RANK receptor induces receptor trimerization and 
recruitment of TRAF6 to bind RANK receptor [124, 125]. P62 subsequently binds to 
TRAF6 through its TB motif, and facilitates TRAF6 Lys63-linked polyubiquitination 
[126], since TRAF6 is an RING domain-containing E3 ligases [127, 128]. In addition, 
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TRAF6 could catalyze the K63-linked polyubiquitination of TAB1-TAB2-TAK1 
complex [129], which activates the IκB kinase (IKK). Moreover, atypical protein kinase 
C (aPKC) is activated by interaction with p62 through its PB1 domain, and further 
activates the IKK [95]. Activated IKK further phosphorylates IκB, and IκB will be 
degraded by 26 S proteasome. Transcription factor NF-κB is then released from IκB and 
translocates from the cytosol to the nucleus, activating the transcription of target genes 
related to the osteoclast formation [130]. The pathway is illustrated in Fig. 1.5. In 
addition, Osteoprotegerin (OPG) negatively regulate RANKL-induced NF-κB signaling 
by competitive binding of RANKL with RANK receptor [131]. 
In our study, we studied the impact of PDB-associated p62 mutants on RANKL-
induced NF-κB signaling. However, the lack of appropriate cell lines prevented us from 
further investigation. 
 
TNFα-induced NF-κB signaling 
Tumor necrosis factor α (TNFα) is an important cytokine involved in 
inflammation, cellular homeostasis and tumor progression and apoptosis [132, 133]. 
TNFα-induced NF-κB activation is similar to RANKL-induced NF-κB signaling 
discussed above, but also has its own characteristics. 
TNFα functions through two receptors, TNF-R1 and TNF-R2 [134]. TNF-R2 is 
exclusively expressed only on endothelial and immune cells. TNF-R1 is universally 
expressed in many cell types, and has been studied more extensively than TNF-R2 [135]. 
TNFα binds TNF-R1 and induces receptor trimerization and leading to the recruitment of  
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the  adaptor protein TNF-R1-associated death domain protein (TRADD) which binds to 
the death domain (DD) of TNF-R1[135]. TRADD protein also recruits TNF receptor-
associated factor 2 (TRAF2), a family protein with TRAF6 mentioned above. TRAF2 is 
an E3 ligase and it could undergo auto-polyubiquitination and ubiquitinates RIP through 
K63-linked polyubiquitin chains. RIP polyubiquitination binds to TAB2/TAB3 complex, 
and recruit TAK1, which phosphorylates IKK, leading to the activation of the IKK 
complex [72]. Moreover, p62 interacts with RIP through its ZZ finger. P62 could also 
interact with aPKC through PB1 domain, and thereby activate IKK [72]. Activated IKK 
further phosphorylates IκB, and IκB will be degraded by the 26S proteasome. 
Transcription factor NF-κB is then released from IκB and translocates from the cytosol to 
the nucleus, activating the transcription of target genes [135]. TNFα-induced NF-κB 
signaling is illustrated in the Fig. 1.5. 
In our study, we investigated the impact of PDB-associated p62 mutations on 
TNFα-induced NF-κB singaling. We found that p62 PDB mutants increased TNFα-
induced NF-κB signaling compared with WT p62. Additionally, we tried to determine the 
molecular mechanisms of the role of p62 PDB mutant in signaling. 
 
Autophagy 
 
In Greek, “autophagy” means “self-eating” [136]. It is another way of protein 
degradation, in addition to ubiquitin proteasome system (UPS) [137]. Autophagy is a 
process for degradation of cellular contents, organelles, misfolded proteins and invading 
bacteria through the lysosomal machinery [138-143]. It contains several different forms, 
including macroautophagy, microautophagy and chaperone-mediated autophagy [85]. 
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Autophagy has emerged as a very active area of investigation as it closely regulates many 
cellular functions. Autophagy is also implicated in many diseases, including alcoholic 
liver disease, neurodegenerative disease and cancer [138, 144-146]. 
Inducers and inhibitors of macroautophagy 
We focus on macroautophagy in our study. The soluble materials and organelles 
in the cytoplasm are sequested by an isolation membrane (also termed “phagophore”). 
Autophagosomes are formed by expansion of the isolation membrane. The 
autophagosome then fuses with the lysosome to become an autophagolysosome (also 
termed “autolysosome”) where the enclosed substrates are degraded (Fig. 1.7 A) [85]. 
Currently, several autophagy inducers and inhibitors have been widely used (Fig. 1.7 A) 
[147]. For example, rapamycin is an inhibitor of the mTOR pathway which negatively 
regulates autophagy. Therefore, rapamycin is an inducer for autophagy. NH4Cl and 
Bafilomycin A inhibit the fusion of lysosome and autophagosome, thereby inhibiting 
autophagy. Another common strategy to induce autophagy is starvation [148]. The class 
III phosphatidylinositol 3-kinase (PI3K-III) activates autophagy and 3-MA inhibits PI3K-
III. Therefore 3-MA is another inhibitor for autophagy. In contrast, beclin-1 activates 
PI3K-III. Thus beclin-1 is an inducer for autophagy. Other autophagy inhibitors include 
E64d and pepstatin A, which inhibit the protease activity in the autophagolysosome (Fig. 
1.7 A). 
LC3-II is a marker for autophagosome 
LC3 is widely used as an autophagy marker. In yeast, Atg 8 is the homolog of 
LC3 in human [149, 150]. There are two forms of LC3, LC3-I and LC3-II, in yeast and 
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mammalian cells. LC3-I is cytosolic, whereas LC3-II is conjugated with 
phosphatidylethanolamine (PE) and is mainly present in isolation membranes, 
autophagosomes and much less on autolysosomes. Therefore, LC3-II serves as a marker 
for autophgosomes. The conversion of LC3-I to LC3-II requires the Atg5-Atg12 complex 
(Fig. 1.7 B) [151]. 
It seems that the increase of LC3-II indicates more autophagosome and higher 
autophagic activity. However, LC3-II is also degraded by autophagy, making it difficult 
to interpret autophagy activity solely based on LC3-II level. Therefore, lysosomal 
protease inhibitors (E64d and pepstatin A) and inhibitors for the fusion of lysosome and 
autophagosomes (NH4Cl and Bafilomycin A) are commonly used in the studies to help 
determine whether autophagic activity is truly increased [152]. It is important to compare 
the amount of LC3-II in the presence and absence of these inhibitors. 
Methods for studying autophagy also include counting the number of GFP-LC3 
puncta in cells overexpressing GFP-LC3. 
 
P62 is both a substrate and regulator of autophagy 
P62 is a specific substrate of autophagy [153]. It can bind LC3 on the 
autophagosome through LIR domain (Fig. 1.4 A) [152]. P62 proteins which have 
mutations in LIR region are not degraded by autophagy, result in their accumulation 
followed by inclusion formation [8]. Therefore, it is suggested that p62 is degraded by 
autophagy through interaction with LC3 directly. In addition, p62 mutations in PB1 
domain are defective in oligomerization. Lower autophagic degradation of these p62 
mutants indicates that oligomerization of p62 through PB1 are critical for their 
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degradation by autophagy [8].  Besides, the level of p62 is upregulated in Atg5 -/- MEFs, 
suggesting that accumulation of p62 could serve as an indicator of autophagy suppression 
[152]. The steady-state level of p62 has recently been used as a marker of autophagic 
degradation activity. For instance, an elevated level of p62 would be interpreted as 
inhibition or failure of autophagic activity [154]. However, this involves the critical 
assumption that p62 biosynthesis is not itself regulated. It has been reported that p62 can 
be induced at the transcriptional level by various stresses including oxidative stress [155, 
156] or proteasome inhibition [157]. Thus, caution should be exercised when using the 
p62 level as a marker of autophagic activity. 
On the other hand, p62 is also a regulator of autophagy. P62 binds the 
polyubiquitinated protein aggregates through its UBA domain. P62, which binds 
polyubiquitinated proteins, could also oligomerize through PB1 domains. It is indicated 
that the interaction of p62 and LC3 is involved in linking polyubiquitinated protein 
aggregates to autophagy [8, 106, 158] (Fig. 1.6). Therefore, p62 is not only a substrate for 
autophagy, but it also regulates the autophagic activity of other proteins. 
In our study, we mainly investigated the impact of PDB-associated p62 mutations 
in autophagy. 
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Figure 1.1. SUMOylation conjugation pathway. SUMO conjugation needs E1 SUMO-
activating enzyme, E2 SUMO-conjugating enzyme (Ubc9) and E3 SUMO ligase, which 
is similar to ubiquitin conjugation. SUMO could also be removed by deconjugating 
enzymes such as the SENP enzymes. This pictures is modified from a review paper 
written by Wilkinson et al. [1]. 
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Figure 1.2. Nuclear SUMOylation substrates and their functions. The well studied 
nuclear SUMOylation substrates could be further classified into nuclear pore complexes, 
transcription factors & coregulators, DNA replication & repair proteins and kinetochore 
& centromere proteins. A delicate balance between SUMOylation and deSUMOylation is 
essential to normal cell functions.  This picture is modified from a review paper written 
by  Zhao [2].  
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Figure 1.3. PDB is a disorder of bone remodeling. Bone mass in human being is 
controlled by both osteoclasts (bone-resorbing cells) and osteoblasts (bone-forming cells). 
The opposing activities of these two cell types ensure bone is constantly remodeled in a 
process essential for maintaining adult bone structure and function [59]. PDB is 
characterized by focal areas of increased bone turnover containing enlarged hyperactive 
osteoclasts [7, 59]. This picture is taken from a review paper written by Layfield (2007) 
[59]. This picture is used with a license agreement between Xiaoyan Liu and Cambridge 
University Press, with a license number 2822601263692. 
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Figure 1.4. Schematic domain structure of p62 and NMR structure of the p62 UBA 
domain.  (A) P62 has different domains which exhibit diverse functions by interacting 
with a number of key proteins. This pictures is modified from a review paper written by 
Moscat et al. [90]. (B) Surface representation of the p62 UBA domain determined by 
protein NMR. Several representative p62 PDB mutations are shown here. This pictures is 
taken from a review paper written by Layfield et al. [111]. Fig. 1.4 B is used with a 
license agreement between Xiaoyan Liu and Springer provided by Copyright Clearance 
Center, with a license number 2822600493041. 
 
(A) 
 
 
(B)  
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Figure 1.5. RANKL-induced and TNFα-induced NF-κB signaling. Upon RANKL or 
TNFα stimulation, TNF-R and RANK receptor undergo trimerization and recruit TRAFs 
to membrane. Briefly, NF-κB signaling is involved in TRAFs polyubiquitination, IKK 
activation, IκB degradation and NF-κB translocation from cytosol to nucleus and 
following target genes expressions. This diagram was drawn in light of a number of 
papers [65, 93-95, 130, 135, 159]. 
 
 
 
 
30 
 
Figure 1.6. P62 is proposed to involve in both ubiquitin proteasome system (UPS) 
and autophagy pathway.  P62 involves in targeting polyubiquitinated proteins for 
degradation by both UPS and autophagy. This picture is modified  from a review paper 
written by Komatsu et al. [8] with permission.  The use of this picture is also permitted 
by the FEBS Letters. 
 
 
 
         
                              Degradation by UPS 
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Figure 1.7. Autophagy pathway. (A) The process of autophagy. Autophagy inducers 
(shown in red) and autophagy inhibitors (shown in blue) are presented here. This picture 
is modified from Dr. Ping Shi’s dissertation in Dr. Haining Zhu’s lab. (B) The conversion 
of LC3-I to LC3-II requires the Atg5-Atg12 complex. This picture is modified from a 
review paper written by Nedelsky et al. [151]. 
(A) 
 
(B) 
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Chapter 2. Proteomic analysis of SUMOylated proteins in mammalian cells 
 
Introduction  
 
 As described in Chapter 1, SUMOylation of proteins are involved in a number of 
diseases including neurodegenerative diseases, cancer and diabetes [14, 160]. Therefore, 
it is important to identify the SUMOylation subtrates and investigate the functional 
consequences of SUMOylation of these substrates, which might shed light on finding the 
therapeutic target for treating these diseases. Identification of SUMOylated proteins has 
remained a challenge because of the low abundance of SUMOylation substrates, a small 
portion of SUMOylated proteins, in addition to the high activity of SUMO deconjugating 
enzymes such as SENP [161]. Quantitative proteomics, using isotope labeling-based 
methods, have been used to identify SUMOylation substrates [162]. Knuesel et al. [163] 
showed that the SUMO-1(T95R) mutant can be used for the identification of the 
SUMOylation site by mass spectrometry in vitro [163]. In light of this study, we 
introduced a relatively simple proteomic method without isotope labeling for 
identification of SUMOylated proteins, which had not been previously reported. 
Furthermore, Knuesel et al. [163] was unable to determine whether this hSUMO-
1(T95R) mutant was still functional in vivo.  In our current study, we demonstrated 
whether that this mutant retained its functionality in HEK cells.  
          Most reported substrates for SUMOylation are nuclear proteins, though a few 
cytosolic proteins have been shown to be substrates [24, 36, 164]. Given this lack of 
knowledge about cytosolic SUMOylation targets, we were particularly interested in novel 
cytosolic protein targets.  
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In this Chapter, we aim to identify novel SUMOylation substrates in mammalian 
cells by using our newly developed proteomic method. The most important advantage of 
our strategy is that, it is an isotope-labeling free method, which is easier compared with 
isotope-labeling method. Especially, we expect to identify novel cytosolic protein as 
SUMOylation substrates. For the potential novel SUMOylation subtrates identified by 
mass spectrometry analysis, we should firstly validate SUMOylation of these proteins by 
other methods, such as immunoprecipitation and Western blotting. Next, we need to find 
the potential SUMOylation sites of these novel substrates. Finally, we would like to 
investigate the functional consequences of these novel SUMOylation substrates.       
 
Materials and methods 
 
cDNA cloning of human SUMO-1 gene 
Total RNA was extracted from HEK293 cells using Qiagen RNA extraction kit 
following the manufacturer’s instruction. Human SUMO-1 full-length cDNA (“SUMO-
1-FL”) was amplified with the following two primers containing two restriction sites at 
each end: 5’ -GC GGA TCC ATG TCT GAC CAG GAG GCA AAA CC-3’ and 5’-GC 
GCGGCCGC CTA AAC TGT TGA ATG ACC CCC TCT TTG- 3’ using cDNA RT-
PCR amplification kit (Invitrogen). Human SUMO-1 cDNA lacking the last four amino 
acids with GG bases at the C-terminal end, was amplified with the following two primers 
containing two restriction sites at each end: 5’-GC GGA TCC ATG TCT GAC CAG 
GAG GCA AAA CC-3’ and 5’-GC GCGGCCGC CTA AAC TGT TGA ATG ACC CCC 
TCT TTG -3’ using cDNA RT-PCR amplification kit (Invitrogen) (“SUMO-1-GG”). The 
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amplified PCR products were recovered using a PCR purification kit (Qiagen), digested 
with HindIII and BamHI and then ligated into the p3xFLAG-CMV-10 expression vector 
(Sigma, St Louis, MO, USA) digested with HindIII and BamHI. The positive clones 
containing the correct inserts were sequenced, and were named pCMV-3xFLAG-SUMO-
1-FL (“SUMO-1 FL” or “FL”, full length) and pCMV-3xFLAG-SUMO-1-GG 
(“SUMO1-GG” or “GG”, last four amino acids truncated), respectively. 
Plasmids construction 
SUMO-1 FL plasmid with the T95R mutation was amplified from the pCMV-
3xFLAG-SUMO-1-FL construct by PCR using two primers containing the following 
sequences: 5’-GC AAG CTT ATG TCT GAC CAG GAG GCA AAA CC-3’ and 5’-GC 
GCGGCCGC CTA AAC TGT TGA ATG ACC CCC TCT TTG-3’. SUMO-1 GG (last 
four amino acids truncated) with the T95R mutation was amplified from the pCMV-
3xFLAG-SUMO-1-GG construct by PCR using two primers containing the following 
sequences:  5’-GC AAG CTT ATG TCT GAC CAG GAG GCA AAA CC-3’ and 5’-GC 
GCGGCCGC CTA ACC CCC TCT TTG TTC CTG ATA-3’. The amplified DNA 
fragments were inserted into the HindIII and NotI sites of the pCMV-3xFLAG-10 vector 
(Sigma). The positive clones were named “SUMO-1-FL-T95R” (or “FL-T95R”, full 
length with T95R mutation) and “SUMO-1-GG-T95R” (or “GG-T95R”, last four amino 
acids truncated, with T95R mutation), respectively. 
       The original Drebrin construct was a gift from Drs. Tomas Brdickac and Ondrej 
Hrusaka (Czech Republic) [165]. Drebrin was firstly amplified by PCR by using upper 
and lower primers GJ764 and GJ765 (Appendix II). The amplified DNA fragments were 
inserted into the EcoRI and BamHI sites of p3xHA-CMV-10, and the positive clones 
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containing the correct inserts were sequenced. The positive clones were named p3xHA-
Drebrin (human full-length, WT Drebrin). Drebrin constructs containing various point 
mutations were generated using the QuikChange II Site-Directed Mutagenesis Kit 
(Stratagene), or Quikchange Multi Mutagenesis Kit (Stratagene) based on p3xHA-
Drebrin (WT). The mutagenic primer sequences are summarized in Appendix II. These 
mutations included K185R, K186R, K192R, K270R, K271R, K185R/K186R, 
K270/K271R and the Drebrin mutant in which five Lys are mutated to Arg:  
K185R/K186R/K192R/K270R/K271R (“5-K mutant”).  
 
Cell culture and transient transfection  
 Human embryonic kidney 293 (HEK293) cells were maintained at 37°C with 5% 
CO2 in Dulbecco's modified Eagle's medium (Invitrogen) containing 10% fetal bovine 
serum (FBS), 100 units/ml penicillin and 100 µg/ml streptomycin. Chinese hamster ovary 
(CHO) cells were cultured in classical liquid media: Hams nutrient mixture F12 
( SH3052601;Thermo scientific, HyClone).  
For protein identification by mass spectrometry, 50% confluent cells were 
transfected with the four different 3xFLAG-SUMO-1 constructs mentioned above, and 
the p3xFLAG-CMV-10 control vector using lipofectamine transfection reagent 
(Invitrogen) in a 10cm plate format. For Ran-GAP1 SUMOylation verification by FLAG 
immunoprecipitation (IP), 70% confluent cells were transfected with FLAG-SUMO-1 
(FL) in a 6-well plate format. For Drebrin SUMOylation verification by FLAG and HA 
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IP, 70% confluent cells were transfected with 3xHA-Drebrin (WT) and the different 
mutant 3xHA-Drebrin constructs in a 6-well plate format. 
 
In-gel digestion and gel extraction  
          After FLAG-IP, enriched SUMOylated proteins were subjected to 10% SDS-
PAGE. The gel was washed twice with fix buffer (50% methanol and 7% acidic acid), 
and was then stained with SYPRO Ruby (S-12000; Invitrogen) overnight (Fig. 2.2). The 
next day, the gel was washed twice with wash buffer (10% methanol and 7% acidic acid). 
Each lane of gel was cut into seven or eight bands, and these bands were subsequently cut 
into the small pieces. These gel pieces were then washed three times with 50% ACN, 
25mM NH4HCO3 (AMBIC) pH 8.0, dried with a SpeedVac and reduced with 10mM 
DTT/50mM AMBIC at 56°C for 45 minutes. Next, proteins were alkylated with 55mM 
IAA/50mM AMBIC at room temperature for 30 minutes in the dark. Following the wash 
with 25mM AMBIC, the gel pieces were dehydrated with 100% ACN and then dried 
using a SpeedVac for 10 minutes. The gels pieces were then incubated with 10ng/µl 
trypsin in 25mM AMBIC overnight at 37°C. The resulting peptides were extracted using 
200µl 50% ACN and 5% formic acid. The extraction liquid was subsequently transferred 
into a new 0.5ml low retention tube and concentrated to 20 µl. 
Mass spectrometry analysis 
          The peptides were subjected to Liquid Chromatography/Mass Spectrometry/Mass 
Spectrometry (LC-MS/MS) analysis, and the electrospray MS/MS data were collected 
from a Q-Star XL quadruple time-of-flight (TOF) mass spectrometer (ABI/MDS Sciex, 
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Foster City, CA, USA) using a nano-flow HPLC system (Eksigent, Dublin, CA, USA). 
For direct infusion electrospray ionisation- mass spectrometry (ESI-MS) analysis, the 
sample was diluted 10 times with 90% acetonitrile containing 0.1% formic acid and 
loaded to Au/Pd-coated spray emitter (Proxeon, Odense, Denmark). The electrospray 
voltage was 2100 V and the mass range of TOF MS was from 350 to 1600 (m/Z). Nano-
flow LC-MS/MS was performed by exploiting the nano-HPLC system for sample pick-
up and separation, where the desired volume of sample solution was injected by the 
autosampler, desalted on a trap column (300 µm i.d. x 5 mm; LC Packings), and was then 
subsequently separated by reverse phase C18 column (75 µm i.d. x 150mm; Vydac) at a 
flow rate of 200 nL/minutes. The HPLC gradient was linear from 5% to 75%  in 55 
minutes using mobile phase A (H2O, 0.1% formic acid) and B (80% acetonitrile, 0.1% 
formic acid). Data acquisition was performed using information-dependent mode, where 
each cycle typically consisted of a 1s TOF MS survey from 350 to 1600 (m/z) and two 2s 
MS/MS scans with mass range of 100-1600 (m/z). 
Protein identification and data analysis  
          LC-MS/MS data were subjected to database searches for protein identification 
using a local MASCOT search engine, and candidate proteins were generated by 
searching the Swiss-Prot database. LC-MS/MS data were also submitted to the MASCOT 
server for MS/MS ion search, and the peak lists from the LC-MS/MS spectra were 
generated by the MASCOT script embedded in the Analyst QS software using the 
following parameters: no smoothing, charge state determined from the MS scan, 
precursor ion charge states of 2+ and 3+, centroid MS/MS data, height percentage 50% 
and merge distance 0.02 Da. The typical parameters used in the MASCOT MS/MS ion 
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search are: Homo sapiens, maximum of three trypsin missed cleavages, “Ubi-GG-Lys” 
definition, cysteine carbamiodomethylation, methionine oxidation, protein N-term 
Acetylation, a maximum of 100 ppm MS error tolerance and a maximum of 0.5 Da 
MS/MS error tolerance. For MS/MS ion search, proteins with one peptide ion scoring 
higher than 20 were considered an unambiguous identification without manual inspection. 
All other hits were manually verified by confirming the peptide sequences from the 
MS/MS spectra. Non-specific proteins from empty vector were eliminated from the 
protein list generated from other four different SUMO-1 samples.  
 
Gene ontology (GO) database 
          The identified common SUMOylated protein list was subjected to the Gene 
Ontology (GO) database, and these proteins were classified based on their location of the 
cell. These locations included nucleus, cellular membrane, cytosol, cytoskeleton, 
chromosome, mitochondrion, extracellular and unannotated location.  
 
Immunoprecipitation  
          Forty-eight hours after transfection, cells were washed with 1x phosphate-buffered 
saline (PBS) and lysed using 1x radio immunoprecipitation assay (RIPA) buffer 
(Millipore) supplemented with protease inhibitor cocktail (P-8340; Sigma, St Louis, MO, 
USA), 0.625 mg/mL N-ethylmaleimide (Sigma), 1 mM sodium o-vanadate (Sigma) and 
0.2 mM phenylmethylsulfonyl fluoride (Sigma).  
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          The FLAG immunoprecipitations were performed by anti-FLAG M2 affinity gel 
(F2426; Sigma) in a final volume of 500 μl containing 1 mg protein extract. The IP 
samples and the corresponding extracts were subjected to sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) followed by Western blotting using the 
following antibodies: anti-Ran-GAP1 (gift from Dr. Kevin Sarge, University of 
Kentucky), anti-FLAG (A8592; Sigma), anti-actin (sc-1616; Santa Cruz Biotechnology) 
and anti-HA (mouse, sc-7392; Santa Cruz Biotechnology).  
     The hemagglutinin (HA) IPs were performed by using 2 μg of a mouse monoclonal 
anti-HA antibody (mouse, sc-7392; Santa Cruz Biotechnology) and Protein-G Sepharose 
(17-0618-01; GE Healthcare). The IP samples and the corresponding extracts were then 
subjected to SDS-PAGE followed by Western blotting using the following antibodies: 
anti-FLAG (A8592; Sigma), anti-actin (sc-1616; Santa Cruz Biotechnology) and anti-HA 
(rabbit, sc-805; Santa Cruz Biotechnology).  
 
Western blotting and quantification  
Nitrocellulose membrane was incubated in blocking solution, 5% milk in Tris-
Buffered Saline and Tween 20 (TBST) for one hour. Then the membranes were incubated 
with primary antibody for more than three hours. After four washes with TBST for five 
minutes each, the membrane was incubated with the secondary antibody for more than 
one hour. After four washes again with TBST for five minutes each, proteins of interest 
were visualized by either normal or dura enhanced chemiluminescent (ECL) substrate 
(Thermo scientific) for detection of horseradish peroxidase (HRP) enzyme (Thermo 
scientific). The membrane was covered with the wrapping membrane and an 
autoradiography film (Denville Scientific) which was exposed to the membrane. The 
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exposure time varied from one second to 20 minutes depending on the signal intensity. 
Films were subsequently developed by a Kodak X- OMAT 2000 processor.  
Software Image J was used for quantification of Western blotting bands on X-ray 
films. Since ECL signals of the Western blot were captured on X-ray films which are 
known to have a narrow linear range of detection, the quantification of the Western blot 
may be out of linear range for certain experiments. Enhanced chemofluorescence (ECF) 
substrate and Alkaline Phosphatase (AP)-conjugated secondary antibody are encouraged 
for use in the future.  
 
Bioinformatic analysis  
SUMOylation sites were predicted using the online software SUMOsp 2.0 
(http://www.sumosp.biocuckoo.org/prediction.php). This software was used to analyze 
all the candidate SUMOylated proteins in the list (Table 2.1). In addition, AlignX Module 
Vector NTI (Invitrogen) was used to align the predicted SUMOylated region of human 
(Homo sapiens), mouse (Mus musculus), rat (Rattus norvegicus), rabbit (Oryctolagus 
cuniculus), horse (Equus caballus), cattle (Bos taurus), african elephant (Loxodonta 
africana), giant panda (Ailuropoda melanoleuca), domestic dog (Canis familiaris), 
opossum (Monodelphis domestica), chicken (Gallus gallus), lizard (Anolis carolinensis), 
african clawed frog (Xenopus laevis) and zebrafish (Daniorerio) (Fig. 2.7 C).   
 
Immunostaining and confocal microscopy  
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Chinese hamster ovary (CHO) cells at 30%-40% confluency were transfected 
with HA-Drebrin (WT and mutants) using lipofectamine reagent (Invitrogen) on gelatin-
coated coverslips. Twenty-four hours post-transfection, cells were fixed with 4% 
paraformaldehyde (PFA) at 37 °C for 15 minutes, permeabilized with PBS/0.1% Triton, 
and blocked with 3% bovine serum albumin (BSA) in PBS for 1 hour. All the primary 
and secondary antibodies were diluted in 3% BSA/PBS. Cells were first stained with 
primary antibody HA (mouse, sc-7392; Santa Cruz Biotechnology, 1:300) or Drebrin 
(ab11068; Abcam, 1:100) for 5.5 hours. The coverslips were then washed with PBS and 
incubated with 4’,6-diamidino-2-phenylindole (DAPI) (D9542; Sigma, 2mg/ml, 1:2000),  
Oregon Green 488 phalloidin (Invitrogen, 1:50), secondary antibody Alexa Fluor 594 
anti-mouse (A21203; Invitrogen 1:300), or Alexa Fluor 594 anti-rabbit, (A11012; 
Invitrogen 1:300) for 1 hour. Finally, the coverslips were mounted using Vectashield 
mounting medium (Vector Laboratories). Fluorescence microscopy was used by a Leica 
SP5 inverted confocal microscope with a 40X objective.  
 
Protrusion quantification and statistical analysis 
For each sample, 10 view images with Z-stack were taken by a Leica SP5 
inverted confocal microscope with a 40X objective. Each view contained about 20-30 
cells. The numbers of protrusions were counted for each cell which has protrusions.  The 
percentage of cells with protrusions was counted. The data were presented as mean with 
standard deviation (SD) based on these 10 view images. The significant differences in 
percentage of cells with protrusions between cells expressing WT Drebrin and mutant 
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Drebrin were analyzed by one-way ANOVA, with Tukey’s post-test using the software 
GraphPad Prism 5 Demo.  
 
Results 
Generation of different versions of 3xFLAG-SUMO-1 fusion protein  
 
           The arginine residue at the C-terminus of ubiquitin could be recognized and 
cleaved by trypsin, leaving a diglycine signature peptide for identification of 
ubiquitination site by mass spectrometry [166, 167]. However, for human SUMO-1, the 
C-terminal end is “TGG” instead of “RGG”, thus it is impossible to generate the 
diglycine signature peptide. In addition, the last lysine or arginine residues of SUMO-1 
are considerably distant from the C-terminus end, generating a SUMO tag 
(ELGMEEEDVIEVYQEQTGG) that is too big for detection by tandem mass 
spectrometry.  
         To solve this problem, we mutated the Thr95 residue of SUMO-1 to Arg. Thus, if 
endogenous SENPs in HEK293 cells correctly recognize and process the mutant 
construct, the last four amino acids of SUMO-1 will be removed. This cleavage of 
SUMO-1 (“FL-T95R”) would yield a 114.1 Da diglycine signature tag (“GG-tag”) 
following trypsin digestion, which could be used for identification of SUMOylation site 
with high confidence. Considering that endogenous SENP might not work efficiently to 
remove the last four amino acids of SUMO-1, we also removed the last four amino acids 
manually to generate the “SUMO-1-GG” (“GG”, last four amino acids truncated) and 
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“SUMO-1-GG-T95R” (“GG-T95R”, last four amino acids truncated, with T95R 
mutation)  (Fig. 2.1). 
 
Identification and classification of SUMOylated proteins from HEK293 cells 
overexpressing four different versions of SUMO-1  
 
SUMOylated proteins were immunoprecipitated from cell lysates of HEK293 
cells overexpressing four different FLAG tagged SUMO-1 plasmids including “FL” (full 
length), “FL-T95R” (full length with T95R mutation), “GG” (last four amino acids 
truncated) and “GG-T95R” (last four amino acids truncated, with T95R mutation). The 
enriched SUMOylated proteins were then subjected to in-gel digestion, and the resulting 
peptides were extracted and subjected to LC-MS/MS analysis.  The LC-MS/MS data 
were subsequently subjected to MASCOT MS/MS ion search. 
Proteins with one peptide ion scoring higher than 60 or two peptide ions scoring 
higher than 30 were considered unambiguous identification without manual inspection. 
The ion score filter is 20. All other hits were manually verified by confirming the peptide 
sequences from the MS/MS spectra. Non-specific proteins from control samples were 
eliminated from all other four samples. The number of proteins identified in cells 
expressing “FL” SUMO-1 (full length), “FL-T95R” SUMO-1 (full length with T95R 
mutation), “GG” SUMO-1 (last four amino acids truncated) and “GG-T95R” SUMO-1 
(last four amino acids truncated, with T95R mutation) are 129, 213, 217 and 177, 
respectively (Fig. 2.3 A). There are 74 identified common SUMOylated proteins among 
these four samples (Table 2.1). In these 74 proteins, two proteins have GG-tag. One is 
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Ran GTPase-activating protein 1 (Ran-GAP1) (RAGP1_HUMAN), the other is T-
complex protein 1 subunit delta (TCP-1-delta) (TCPD_HUMAN) (Table 2.2). 
Additionally, there are 88 common proteins identified from cells overexpressing “FL” 
SUMO-1 (full length) and “GG-T95R” SUMO-1 (last four amino acids truncated, with 
T95R mutation) (Fig. 2.3 B). 
As described above, a total of 177 unique proteins were identified from the 
purified SUMOylated proteins in cells overexpressing “GG-T95R” SUMO-1 (last four 
amino acids truncated, with T95R mutation) (Fig. 2.3 A). There were 13 proteins 
identified with GG-tag from cells overexpressing “GG-T95R” SUMO-1 (last four amino 
acids truncated, with T95R mutation) when cutoff was 20 (Table 2.2).  
The above 74 identified common SUMOylated proteins were classified by 
subcellular location using the Gene Ontology (GO) databases, and these proteins were 
classified into nucleus, membrane, cytosol, cytoskeleton, chromosome, mitochondrion, 
extracellular and unannotated (Fig. 2.4). Among these 74 identified common 
SUMOylated proteins, most protein (51.4%) were located in the nucleus, 28.4% protein 
were located into membrane, 21.6% protein were located in the cytosol, 16.2% protein 
were located in the cytoskeleton, 12.2% protein were located in the chromosome, 9.5% 
protein were located in the mitochondrion, 6.8% protein were extracellular and 6.8% 
protein were unannotated (Fig. 2.4). 
 
Validation of Ran-GAP1 SUMOylation by MS/MS spectra and IP  
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 Ran-GAP1 was the first identified SUMOylated protein [12] and was also in our 
candidate SUMOylation protein list (Table 2.1). Thus, we have again validated Ran-
GAP1 SUMOylaton using MS/MS spectra (Fig. 2.5) and IP (Fig. 2.6). The successful 
validation of Ran-GAP1 could serve as a positive control for our proteomic method.  
First, we validated Ran-GAP1 SUMOylation by MS/MS spectra. If Ran-GAP1 is 
SUMOylated, after trypsin digestion, it will generate a peptide with a GG-tag. Then after 
fragmentation, it will generate a lysine residue (128.09 Da) with two glycine residue 
(114.04 Da), a total 242.1379 Da. Indeed, here we found the MS/MS spectra of peptide 
LLVHMGLLK*(GG)SEDK derived from digestion of Ran-GAP1. This peptide was 
fragmented into a, b, c, x, y and z series ions. The molecular weight of y4 ion is 478.1643 
and molecular weight of y5 ion is 720.2861. The difference between y4 and y5 ion is 
242.1218, which is exactly the molecular weight of lysine and two glycine mentioned 
above, representing the GG tag generated by trypsin digestion (Fig. 2.5). Therefore, it is 
shown that Ran-GAP1 is SUMOylated by MS/MS spectra.  
Next, HEK293 cells were transfected with “FL” SUMO-1 (full length) or “GG-
T95R” SUMO-1 (last four amino acids truncated, with T95R mutation). Forty-eight 
hours post-transfection, FLAG-SUMO-1 IP was performed, and IP products were 
subjected to SDS-PAGE. Western blotting was performed using antibodies against Ran-
GAP1, FLAG and actin. SUMOylated Ran-GAP1 was shown in IP products from cells 
overexpressing either “FL” SUMO-1 or “GG-T95R” SUMO-1, but not in the control 
samples (Fig. 2.6). Therefore, it is again shown that Ran-GAP1 is SUMOylated by IP and 
Western blotting.  
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Identification and validation of SUMOylation of a novel substrate named Drebrin  
 
We also used the software SUMOsp 2.0 to predict SUMOylation sites for all the 
candidate SUMOylation proteins in our list (Table 2.1). Among these 74 common 
proteins, 40 proteins (54%) have SUMOylation consensus sequences, 61 proteins (82%) 
have predicted SUMOylation sites including both SUMOylation consensus sites and non-
SUMOylation consensus sites (Table 2.1).  
Our candidate SUMOylation protein list (Table 2.1) includes a protein called 
Drebrin. As described in Chapter 1, Drebrin is an actin-binding protein involved in the 
formation of neurites and cell protrusions [44]. Unlike nuclear proteins that comprise the 
majority of SUMOylation substrates, Drebrin is a cytosolic actin-binding protein [45, 56]. 
The SUMOsp2.0 software showed that Drebrin had four predicted SUMOylation sites, in 
which one is a SUMOylation consensus motif, and the other three are non-consensus type 
(Table 2.1 and Fig. 2.7 A). We also aligned this predicted SUMOylated region among 
different species. This region was shown to be highly conserved among vertebrate 
species, suggesting that this region is functionally important (Fig. 2.7 C). Consistently, a 
previous report states that the Drebrin protein is highly conserved, especially at the N-
terminal (residues 1-315) [44].               
          We verified Drebrin SUMOylation by both FLAG-SUMO-1 IP and HA-Drebrin IP. 
In detail, we first verified Drebrin SUMOylation by FLAG-SUMO-1 IP. HEK293 cells 
were transfected with “FL” SUMO-1 (full length) or “GG-T95R” SUMO-1 (last four 
amino acids truncated, with T95R mutation). Forty-eight hours post-transfection, FLAG-
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SUMO-1 IP was performed and IP products were subjected to SDS-PAGE. Western 
blotting was performed using antibodies against Drebrin with longer and short exposure 
time. SUMOylated Drebrin is shown in both cells expressing “FL” SUMO-1 and “GG-
T95R” SUMO-1, not in the control cells (Fig. 2.8 A, long exposure), suggesting that 
Drebrin is SUMOylated by FLAG-SUMO-1 IP. Also, the SUMOylation level of Drebrin 
is higher in cells expressing “FL” SUMO-1 than “GG-T95R” SUMO-1 (Fig. 2.8 A). 
          In addition, we verified Drebrin SUMOylation by HA-Drebrin IP. HEK293 cells 
were transfected with HA-Drebrin (WT) and FLAG-SUMO-1 (full length). Forty-eight 
hours post-transfection, HA-Drebrin IP was performed and IP products were subjected to 
SDS-PAGE. Western blotting was performed using antibodies against FLAG, HA and 
actin. SUMOylated Drebrin was observed in cells expressing both HA-Drebrin and 
FLAG-SUMO-1, but not in control cells (Fig. 2.8 B), indicating that Drebrin is 
SUMOylated by HA-Drebrin IP.   
 
K185, K186, K270 and K271 are potential SUMOylation sites of Drebrin  
 
We next aimed to find potential SUMOylation sites of Drebrin. According to the 
SUMOylation consensus sequence ΨKXE/D [1], Drebrin has four predicted 
SUMOylation sites including one SUMOylation consensus site, AKKE (amino acid 184-
187) and three non-consensus sites, which are KKEE (amino acid 185-188), RKEE 
(amino acid 191-194) and KKSE (amino acid 270-273) (Fig. 2.7 B). These sites are also 
conserved among a number of different species (Fig. 2.7 C).  
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By using the site-directed mutagenesis, we generated several Drebrin single 
mutants through changing the K185, K186, K192, K270 and K271 of Drebrin to R 
respectively. Also, we generated double mutants including K185R/K186R and 
K270R/K271R. Additionally, we generated a mutant in which all the five K are mutated 
to R, K185R/K186R/K192R/K270R/K271R, called “5-K mutant”. 
          Then, we performed both FLAG-SUMO-1 IP and HA-Drebrin IP in HEK293 cells 
overexpressing FLAG-SUMO-1 (full length) and a variety of different HA-Drebrin 
mutants including double mutations K185R/K186R, K270R/K271R, single mutant 
K192R and “5-K mutant” in which all the five K were mutated to R. IP products were 
subjected to SDS-PAGE and Western blotting was performed using antibodies against 
HA, FLAG and actin (Fig. 2.9 A and B). Interestingly, the SUMOylation level of mutant 
Drebrin (combined mutations K185R/K186R) was much less (50% reduction) than that 
of WT Drebrin (Fig. 2.9 B, lane 3). Also, the SUMOylation level of mutant Drebrin 
(combined mutations K270R/K271R) was slightly less (30% reduction) than that of WT 
Drebrin (Fig. 2.9 B, lane 5). 
          Therefore, these data suggest that potential Drebrin SUMOylation sites could be 
K185, K186, K270 and K271.  To further clarify which K is SUMOylated, we performed 
the HA-Drebrin IP using the single Drebrin mutant, our preliminary data showed that no 
single lysine mutant (K185R, K186R, K270R or K271R) could abolish the SUMOylation 
level of Drebrin (data not shown). Clarification of this issue requires additional 
experiments. 
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Double mutation (K185R/K186R and K270R/K271R) in Drebrin separately did not 
appear to change protrusion formation 
 
          As described in Chapter 1, previous studies have demonstrated that Drebrin plays 
an important role in the formation of filopodia [53, 54, 57]. Also, we have shown that 
mutant K185R/K186R and K270R/K271R impair Drebrin SUMOylation compared with 
WT Drebrin. The next questions would be whether these two mutants also change the 
formation of filopodia compared with WT Drebrin. In order to address this question, 
CHO cells were transfected with HA-Drebrin (WT, K185R/K186R or K270R/K271R). 
Twenty-four hours post-transfection, immunostaining was performed using either HA or 
Drebrin antibody for staining Drebrin, Oregon Green 488 phalloidin for staining actin 
and DAPI for staining nucleus. Confocal microscopy was used to observe cellular 
protrusions (Fig. 2.10 A). 
          Consistent with the literature [53, 54, 57], we observed obvious cellular protrusions 
in cells overexpressing Drebrin (WT and mutants) (Fig. 2.10 A). However, after we 
quantified the percentage of cells with protrusions from 10 view images (each image was 
selected from five Z-stack images) for each sample, we found that there was no 
significant change among cells expressing WT Drebrin and Drebrin mutants (Fig. 2.10 B). 
Therefore, our preliminary results suggested that mutation of these two sites 
(K185R/K186R and K270R/K271R) in Drebrin separately did not appear to change 
protrusion formation. 
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Discussion  
 
An applicable proteomic method for identification of SUMO substrates 
  
 Previous proteomic method for identification of SUMO substrates is using 
isotope-labeling method, which is complex [162]. In this Chapter, we developed a 
relatively simple proteomic method to identify SUMOylated proteins in HEK293 cells 
based on previous studies [163, 167]. First, we generated a number of SUMO-1 
constructs to facilitate identification of SUMOylated proteins by mass spectrometry. In 
detail, we mutated the Thr95 of SUMO-1 to Arg (“FL-T95R” SUMO-1, full length, with 
T95R mutation). Since endogenous SENPs remove the last four amino acids of SUMO-1, 
it could yield a GG-tag after trypsin digestion and facilitate the identification by mass 
spectrometry [163, 167]. Considering that SENPs may not work very efficiently, we 
further removed the last four amino acids manually, and generated “GG-T95R” SUMO-1 
(last four amino acids truncated, with T95R mutation). For comparison, we also 
generated a SUMO-1 plasmid without the last four amino acids but retained Thr 95, 
called “GG” SUMO-1 (last four amino acids truncated). Together with full length 
SUMO-1 (“FL”), these four different versions of SUMO-1 are all FLAG tagged (Fig. 2.1), 
and served for enriching SUMOylated proteins by FLAG-IP. The IP products were 
subjected to in-gel digestion and mass spectrometry for analysis. 
After eliminating the non-specific proteins, 74 common SUMOylated proteins 
were identified from cells expressing four different SUMO-1 constructs. These 74 
proteins are considered as candidate SUMOylated proteins. In this protein list, three 
proteins were reported before as SUMOylation substrates including Ran-GAP1 [12], 
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nucleophosmin (NPM) [168] and proliferating cell nuclear antigen (PCNA) [169] (Table 
2.1). Also, 16 proteins were found in the articles related to the SUMOylation in PubMed 
database. In addition, we predicted SUMOylation sites including SUMO consensus sites 
(ΨKXE/D) and non-consensus sites for all these 74 proteins using software SUMOsp 2.0. 
The numbers of consensus and non-consensus sites of each protein are shown in Table 
2.1. Among these 74 common proteins, 40 proteins (54%) have SUMOylation consensus 
sequences, and 61 proteins (82%) have predicted SUMOylation sites including 
SUMOylation consensus sites and non-SUMOylation consensus sites (Table 2.1). 
Additionally, 51.4% of these 74 identified common SUMOylated proteins are nuclear 
proteins, consistent with the observations that most identified SUMOylated proteins are 
located within the nucleus [2]. Moreover, we successfully verified the SUMOylation of 
Ran-GAP1, the first identified SUMOylation substrate [37] in our system by MS/MS 
spectra (Fig. 2.5) and IP (Fig. 2.6). The successful validation of Ran-GAP1 could serve 
as a positive control for our proteomic method. Altogether, we have developed an 
applicable proteomic method for identification of SUMO substrates. 
 
A novel substrate for SUMOylation, a cytosolic protein called Drebrin 
 
Currently, not many cytosolic SUMOylation substrates have been found [24, 36]. 
To fill this gap, we identified and validated SUMOylation of a cytosolic protein, called 
Drebrin. In our study, we identified a novel cytosolic SUMO substrate, Drebrin. We 
verified Drebrin SUMOylation by both FLAG-IP and HA-IP in HEK293 cells 
overexpressing FLAG-SUMO-1 and HA-Drebrin (Fig. 2.8 A and B). Drebrin has four 
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predicted SUMOylation sites including one SUMOylation consensus site, AKKE (amino 
acids 184-187) and three non-consensus sites, which are KKEE (amino acids 185-188), 
RKEE (amino acids 191-194) and KKSE (amino acids 270-273) (Fig. 2.7 B). These sites 
are also conserved among a number of different species (Fig. 2.7 C).  
In order to find potential SUMOylation sites of Drebrin, we generated several 
Drebrin single mutants through changing the K185, K186, K192, K270 and K271 to R 
respectively. Also, we generated double mutants including K185R/K186R and 
K270R/K271R. Additionally, we generated a mutant in which all the five K are mutated 
to R, K185R/K186R/K192R/K270R/K271R, called “5-K mutant”. Next, we compared 
the effect of SUMOylation in cells overexpressing these HA-Drebrin mutants and WT 
HA-Drebrin by HA-IP.  Our data showed that the SUMOylation level of Drebrin K185R/ 
K186R was much less than that of WT Drebrin (Fig. 2.9 B, lane 3), about 50% decrease. 
Plus, the SUMOylation level of Drebrin K270R/ K271R is slightly less than that of WT 
Drebrin (Fig. 2.9 B, lane 5), about 30% decrease. 
We are also curious about the functional consequence of SUMOylated Drebrin. It 
was reported that overexpressing Drebrin in CHO cells could cause the formation of 
cellular membrane protrusions [53]. Therefore, we investigated the effect of SUMOylated 
Drebrin on these CHO cells by overexpressing either WT HA-Drebrin or double mutant 
HA-Drebrin (K185R/K186R and K270R/K271R). Consistent with the literature [53, 54, 
57], we observed obvious membrane protrusions in cells overexpressing Drebrin (WT 
and mutants). However, after we quantified the percentage of cells with protrusions from 
10 view images (each image was selected from five Z-stack images) for each sample, 
there was no significant change among cells expressing WT Drebrin and Drebrin mutants 
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(Fig. 2.10 B). Thus, our data suggests that mutation of these two sites (K185R/K186R 
and K270R/K271R) separately did not appear to change protrusion formation. 
 
           
Troubleshooting and further technique development 
 
          Although our proteomic method is applicable as discussed before, several problems 
still remain. Firstly, among the 177 unique proteins identified from the purified 
SUMOylated proteins in cells overexpressing SUMO-1 (GG-T95R) (Fig. 2.3 A), there 
were only 13 protein identified with GG-tag when cutoff was 20 (Table 2.2). 
Additionally, only two of these 13 proteins were in the 74 common protein list (Table 2.1 
and 2.2). Moreover, the evidence of MS/MS spectra for GG-tag was not obvious except 
for Ran-GAP1 (Fig. 2.5). Therefore, GG-tag might not be easy for identification by 
current LC-MS/MS settings. It might due to majority identification of the GG-tags are 
below the current limit of detection. Potential ways to overcome this problem could be 
increasing the amount of enriched SUMOylated proteins subjected to LC-MS/MS by 
increasing cultured cells. Also, more advanced mass spectrometry might help to better 
identify the GG-tag.   
          Another potential problem of our method is that the FLAG-IP is not very specific 
for enrichment of SUMOylated proteins. Although proteins in control cells were 
eliminated, the enriched SUMOylated proteins by FLAG-IP might still be contaminated 
with proteins containing other post-translational modification, such as ubiquitination, 
which is very similar to SUMOylation.  If so, it is difficult to distinguish SUMOylation 
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from ubiquitination in the identified proteins containing GG-tags because they both will 
have GG-tags following tryptic digestion.  One way to get around this problem could be 
using tandem affinity purification (TAP) for better enrichment of SUMOylated proteins.  
A third concern is that the “5-K mutant” Drebrin in which all the five Lys are 
mutated to Arg did not completely abolish SUMOylation compared with WT Drebrin by 
HA-IP (data not shown). Therefore our data suggest that other Lys outside of the 
predicted SUMOylation region (Fig. 2.7 B) might be present. Another possibility is that 
cells have “compensation mechanism”, thus SUMOylation could occur at some random 
Lys when all the SUMOylated Lys are mutated. In addition, the experiments shown in 
Fig. 2.9 B were repeated three times. SUMOylation of K185R/K186R mutant Drebrin 
decreased compared with WT p62 for all three experiments. However, K270R/271R 
mutant Drebrin did not decrease for all three experiments, suggesting again that 
SUMOylation sites might be outside of the predicted SUMOylation region. Clarification 
of this issue requires additional experiments. 
 
Significance of this study and future directions 
 
          Based on a previous study [163], we developed a relatively simple proteomic 
method to identify SUMOylated substrates. We have identified 74 SUMOylated proteins 
by our method, in which three proteins are reported to be SUMOylation substrates, 16 
proteins are related to the SUMOylation substrates, 40 proteins have SUMOylation 
consensus sequences (ΨKXE/D) and 61 proteins have predicted SUMOylation sites by 
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software. We also validated the first SUMOylated protein Ran-GAP1 in our system. 
Therefore, our method is applicable for identifying novel SUMOylation substrates. 
 In addition, we are the first group to report that an actin-binding protein, Drebrin, 
is a substrate for SUMOylation.  It is interesting that Drebrin is not in the nucleus, and 
little is known about SUMO substrates located outside of nucleus [24, 36]. These data 
may expand our knowledge of non-nuclear SUMOylation substrates by studying the 
functional consequence of Drebrin. In our study, we verified Drebrin SUMOylation by IP 
and found that K185, K186, K270 and K271 might be Drebrin SUMOylation sites. Also, 
our data have shown that double mutation (K185R/K186R and K270R/K271R) 
separately did not appear to change protrusion formation (Fig. 2.10 B). Therefore, we 
could further explore the functional consequences of Drebrin in the future. 
Moreover, in our protein list, there are several proteins that have a relatively high 
number of predicted SUMOylation sites (highlighted in Table 2.1). These proteins 
include general transcription factor II-I (four consensus and two non-consensus sites), 
heterogeneous nuclear ribonucleoproteins C1/C2 (two consensus and eight non-
consensus sites), heterogeneous nuclear ribonucleoprotein U (three consensus and five 
non-consensus sites), heterogeneous nuclear ribonucleoprotein D0  (one consensus and 
three non-consensus sites), nucleolin (four consensus and four non-consensus sites), poly 
[ADP-ribose] polymerase 1 (five consensus and 11 non-consensus sites), 60S ribosomal 
protein L24 (two consensus and two non-consensus sites) and spectrin beta chain, brain 1 
(three consensus and 13 non-consensus sites), Ras GTPase-activating-like protein 
IQGAP1 (four consensus and 11 non-consensus sites), ATP-dependent DNA helicase 2 
subunit 1 (two consensus and four non-consensus sites) and myosin-10 (six consensus 
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and 10 non-consensus sites), another cytosolic protein. Future studies could validate 
whether these proteins above are SUMOylation substrates by IP and other methods.  
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Figure 2.1. Schematic diagrams of SUMO-1 constructs in our study. Schematic 
diagrams of four p3xFLAG-SUMO-1 constructs used in our study including “FL” (full 
length), “FL-T95R” (full length with T95R mutation), “GG” (last four amino acids 
truncated) and “GG-T95R” (last four amino acids truncated, with T95R mutation).  
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Figure 2.2. Sypro Ruby staining SDS-PAGE gel of FLAG-SUMO-1 IP from cells 
overexpressing four versions of SUMO-1 constructs.  HEK293 cells were transfected 
with four different SUMO-1 constructs including “FL” (full length), “FL-T95R” (full 
length with T95R mutation), “GG” (last four amino acids truncated) and “GG-T95R” 
(last four amino acids truncated, with T95R mutation). Forty-eight hours post-
transfection, FLAG-SUMO-1 IP was performed and IP products were subjected to SDS-
PAGE. The gel was then stained with Sypro Ruby overnight. Each lane was cut into 
seven or eight bands and the gel was subjected to the in-gel digestion, gel extraction and 
LC-MS/MS.  
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Figure 2.3. Number of identified SUMOylated protein from HEK293 cells 
overexpressing four different versions of SUMO-1 constructs. (A) Numbers of 
SUMOylated proteins identified with high confidence (ion score filter 20) from HEK293 
cell overexpressing four different versions of SUMO-1 constructs including “FL” (full 
length), “FL-T95R” (full length with T95R mutation), “GG” (last four amino acids 
truncated) and “GG-T95R” (last four amino acids truncated, with T95R mutation). There 
are 74 common SUMOylated proteins. Non-specific proteins from control samples were 
eliminated from identified SUMOylated proteins. (B) Number of SUMOylated proteins 
identified with high confidence (Ion score filter 20) from HEK293 cell transfected with 
“FL” (full length) and “GG-T95R” (last four amino acids truncated, with T95R mutation). 
There are 88 common SUMOylated proteins.   
 (A) 
 
(B) 
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Figure 2.4. Classification of 74 identified common SUMOylated proteins. The 74 
common proteins were classified based on the subcellular locations including nucleus, 
membrane, cytosol, cytoskeleton, chromosome, mitochondrion, extracellular and 
unannotated locations by Gene Ontology (GO) databases. The percentage of proteins   
belonging to each subcellular location is also shown.  
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Figure 2.5. MS/MS evidence of SUMOylated peptide from Ran-GAP1. MS/MS 
spectrum of the peptide LLVHMGLLK*(GG)SEDK derived from digestion of Ran 
GTPase-activating protein 1 (Ran-GAP1). Validation of Ran-GAP1 serves as a positive 
control for our proteomic method.  
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Figure 2.6. Validation of SUMOylated Ran-GAP1 by FLAG-SUMO-1 IP followed 
by Western blotting. HEK293 cells were transfected with “FL” SUMO-1 (full length) or 
“GG-T95R” SUMO-1 (last four amino acids truncated, with T95R mutation). Forty-eight 
hours post-transfection, FLAG-SUMO-1 IP was performed and IP products were 
subjected to SDS-PAGE. Western blotting was performed using antibodies against Ran-
GAP1, FLAG and actin.  
 
 
 
 
                 
                     
 
 
63 
 
Figure 2.7. Predicted SUMOylation region of human Drebrin. (A) Predicted 
SUMOylation region of human Drebrin by software SUMOsp 2.0. (B) The predicted 
SUMOylation consensus site is highlighted and the predicted non-consensus 
SUMOylation sites are underlined. The predicted SUMOylated Lys residues are shown in 
red. (C) The sequence alignment of predicted SUMOylation region of Drebrin among 
different species including human (Homo sapiens), mouse (Mus musculus), rat (Rattus 
norvegicus), rabbit (Oryctolagus cuniculus), horse (Equus caballus), cattle (Bos taurus), 
african elephant (Loxodonta africana), giant panda (Ailuropoda melanoleuca), domestic 
dog (Canis familiaris), opossum (Monodelphis domestica), chicken (Gallus gallus), 
lizard (Anolis carolinensis), african clawed frog (Xenopus laevis) and zebrafish (Danio 
rerio).  
 
 
(A) 
 
 
(B) 
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(C) 
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Figure 2.8. Validation of SUMOylated Drebrin by FLAG-SUMO-1 IP and HA-
Drebrin IP followed by Western blotting. (A) Validation of SUMOylated Drebrin by 
FLAG-SUMO1 IP. HEK293 cells were transfected with “FL” SUMO-1 (full length) or 
“GG-T95R” SUMO-1 (last four amino acids truncated, with T95R mutation). Forty-eight 
hours post-transfection, FLAG-SUMO-1 IP was performed and IP products were 
subjected to SDS-PAGE. Western blotting was performed using antibodies against 
Drebrin with longer and short exposure time. (B) Validation of SUMOylated Drebrin by 
HA-Drebrin IP. HEK293 cells were transfected with FLAG-SUMO-1 (full length) and 
HA-Drebrin (WT). Forty-eight hours post-transfection, HA-Drebrin IP was performed 
and IP products were subjected to SDS-PAGE. Western blotting was performed using 
antibodies against FLAG, HA and actin. 
 
(A) 
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(B) 
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Figure 2.9. Identification of Drebrin SUMOylation sites by FLAG-SUMO-1 IP and 
HA-Drebrin IP. (A) Identification of Drebrin SUMOylation sites by FLAG-SUMO-1 IP. 
HEK293 cells were transfected with full length FLAG-SUMO-1 and HA-Drebrin (WT) 
or mutant HA-Drebrin including K185R/K186R, K192R, K270R/K271R and K185R 
/K186R/ K192R /K270R/K271R (“5-K mutant”). FLAG-SUMO-1 IP was performed and 
IP products were subjected to SDS-PAGE. Western blotting was performed using 
antibodies against HA, FLAG and actin. (B) Identification of Drebrin SUMOylation sites 
by HA-Drebrin IP. HEK293 cells were transfected with full length FLAG-SUMO-1 and 
HA-Drebrin (WT) or mutant HA-Drebrin including K185R/K186R, K192R and 
K270R/K271R. HA-Drebrin IP was performed and IP products were subjected to SDS-
PAGE. Western blotting was performed using antibodies against HA, FLAG and actin. 
Quantification of SUMOylated Drebrin/Drebrin was done by Image J software. The 
relative amount of SUMOylated Drebrin was obtained by normalization of SUMOylated 
Drebrin to HA-Drebrin and this number for WT Drebrin was set to 1. All other mutants 
were normalized accordingly. The quantification data is shown in red.  
 (A) 
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 (B) 
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Figure 2.10. Immunostaining of Drebrin and actin filament in CHO cells. CHO cells 
were transfected with WT Drebrin or mutant Drebrin (K185R/K186R or K270R/K271R) 
or empty HA vector. Non-transfected CHO cells also were used as control cells. Twenty-
four hours post-transfection, cells were fixed with 4% PFA and permeabilized with 0.1% 
Triton. Primary antibody HA (1:300) or Drebrin (1:50) and secondary antibody Alexa 
Fluro 594 (mouse or rabbit) (red, 1:300), as well as DAPI (blue, 1:2000), Oregon Green 
488 phalloidin (green, 1:50) were used. Confocal microscopy was applied for observation. 
Scale bars=10 µm.  (A) Immunostaining of Drebrin and actin.  (B) Quantification of % of 
protrusions in each sample. The data were presented as mean ± S.D., and one way 
ANOVA analysis with Tukey’s test was used to analyze the differences between the 
individual experiments.  
(A) 
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(B) 
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Table 2.1.  Seventy-four proteins identified in cells expressing four different SUMO-
1 constructs. Proteins were identified by nano-LC-MS/MS from in-gel tryptic digestion 
followed by MASCOT search.  The number of SUMOylation consensus sites and 
predicted non-consensus SUMOylation sites were analyzed by SUMOsp 2.0 software. A 
number of proteins with higher number of predicted SUMOylation sites (large than four, 
at least one SUMO consensus site) were highlighted. 
Accession Protein Description 
SUMO 
consensus sites 
Non-consensus 
sites 
ACTN4_HUMAN Alpha-actinin-4  
1 3 
ALDOA_HUMAN 
Fructose-bisphosphate 
aldolase A  
0 2 
ATPA_HUMAN 
ATP synthase subunit 
alpha, mitochondrial 
precursor  
1 0 
ATPB_HUMAN 
ATP synthase subunit 
beta, mitochondrial 
precursor  
0 1 
C1TC_HUMAN 
C-1-tetrahydrofolate 
synthase, cytoplasmic 
(C1-THF synthase)  
1 0 
DDX3X_HUMAN 
ATP-dependent RNA 
helicase DDX3X  
1 1 
DDX5_HUMAN 
Probable ATP-dependent 
RNA helicase DDX5  
1 2 
DREB_HUMAN 
Drebrin 
(Developmentally-
regulated brain protein) 
1 3 
EF1D_HUMAN Elongation factor 1-delta  
0 1 
EF1G_HUMAN 
Elongation factor 1-
gamma  
1 1 
EFTU_HUMAN 
Elongation factor Tu, 
mitochondrial precursor  
1 1 
G3P_HUMAN 
Glyceraldehyde-3-
phosphate 
dehydrogenase  
1 2 
GSTM2_HUMAN 
Glutathione S-transferase 
Mu 2  
1 1 
GTF2I_HUMAN 
General transcription 
factor II-I (GTFII-I)  
4 2 
H4_HUMAN Histone H4  
0 0 
  
 Contd. 
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HNRH1_HUMAN 
Heterogeneous nuclear 
ribonucleoprotein H 
(hnRNP H)  
0 2 
HNRPC_HUMAN 
Heterogeneous nuclear 
ribonucleoproteins 
C1/C2  
2 8 
HNRPD_HUMAN 
Heterogeneous nuclear 
ribonucleoprotein D0  
1 3 
HNRPU_HUMAN 
Heterogeneous nuclear 
ribonucleoprotein U  
3 5 
IF4A1_HUMAN 
Eukaryotic initiation 
factor 4A-I  
1 1 
IF5A1_HUMAN 
Eukaryotic translation 
initiation factor 5A-1  
0 1 
IMA2_HUMAN Importin alpha-2 subunit  
0 2 
IMB1_HUMAN Importin beta-1 subunit  
0 3 
IQGA1_HUMAN 
Ras GTPase-activating-
like protein IQGAP1  
4 11 
KU70_HUMAN 
ATP-dependent DNA 
helicase 2 subunit 1  
2 4 
MCM3_HUMAN 
DNA replication 
licensing factor MCM3  
0 5 
MCM4_HUMAN 
DNA replication 
licensing factor MCM4  
1 2 
MCM7_HUMAN 
DNA replication 
licensing factor MCM7  
0 4 
MYH10_HUMAN Myosin-10  
6 10 
MYL6_HUMAN 
Myosin light polypeptide 
6  
0 0 
NOLA1_HUMAN 
H/ACA 
ribonucleoprotein 
complex subunit 1  
0 0 
NONO_HUMAN 
Non-POU domain-
containing octamer-
binding protein  
1 2 
NPM_HUMAN Nucleophosmin (NPM)  
2 3 
NUCL_HUMAN Nucleolin (Protein C23) 
4 4 
Contd. 
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ODPA_HUMAN 
Pyruvate dehydrogenase 
E1 component alpha 
subunit 
0 1 
PARP1_HUMAN 
Poly [ADP-ribose] 
polymerase 1  
5 11 
PCBP1_HUMAN 
Poly(rC)-binding protein 
1  
0 0 
PCBP2_HUMAN 
Poly(rC)-binding protein 
2  
0 1 
PCNA_HUMAN 
Proliferating cell nuclear 
antigen (PCNA)  
1 0 
PLST_HUMAN Plastin-3 (T-plastin)  
0 2 
PPIA_HUMAN 
Peptidyl-prolyl cis-trans 
isomerase A  
1 0 
PRPS1_HUMAN 
Ribose-phosphate 
pyrophosphokinase I  
0 0 
RAN_HUMAN 
GTP-binding nuclear 
protein Ran  
0 0 
RAGP1_HUMAN 
Ran GTPase-activating 
protein 1  
2 1 
RL11_HUMAN 
60S ribosomal protein 
L11  
1 1 
RL14_HUMAN 
60S ribosomal protein 
L14  
1 1 
RL19_HUMAN 
60S ribosomal protein 
L19  
1 4 
RL22_HUMAN 
60S ribosomal protein 
L22  
0 0 
RL24_HUMAN 
60S ribosomal protein 
L24  
2 2 
RL27_HUMAN 
60S ribosomal protein 
L27  
1 0 
RL31_HUMAN 
60S ribosomal protein 
L31  
0 0 
RL38_HUMAN 
60S ribosomal protein 
L38  
0 3 
RL4_HUMAN 
60S ribosomal protein 
L4 (L1)  
0 2 
RL9_HUMAN 
60S ribosomal protein 
L9  
0 1 
ROA1_HUMAN 
Heterogeneous nuclear 
ribonucleoprotein A1  
0 3 
  
 Contd. 
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RS14_HUMAN 
40S ribosomal protein 
S14  
0 2 
RS15A_HUMAN 
40S ribosomal protein 
S15a  
0 0 
RS3A_HUMAN 
40S ribosomal protein 
S3a  
2 0 
RS4X_HUMAN 40S ribosomal protein S4 
0 4 
RS6_HUMAN 40S ribosomal protein S6  
0 4 
SFPQ_HUMAN 
Splicing factor, proline- 
and glutamine-rich  
2 1 
SPTA2_HUMAN 
Spectrin alpha chain, 
brain  
2 9 
SPTB2_HUMAN 
Spectrin beta chain, 
brain 1  
3 13 
SUMO1_HUMAN 
Small ubiquitin-related 
modifier 1 precursor 
(SUMO-1)  
0 0 
TBA3_HUMAN Tubulin alpha-3 chain  
0 0 
TBB2C_HUMAN Tubulin beta-2C chain  
0 0 
TBB3_HUMAN Tubulin beta-3 chain  
0 0 
TCPD_HUMAN 
T-complex protein 1 
subunit delta (TCP-1-
delta)  
0 1 
TCPE_HUMAN 
T-complex protein 1 
subunit epsilon  
1 1 
TCPH_HUMAN 
T-complex protein 1 
subunit eta  
1 3 
TCPW_HUMAN 
T-complex protein 1 
subunit zeta-2  
1 4 
TCPZ_HUMAN 
T-complex protein 1 
subunit zeta  
2 4 
TIF1B_HUMAN 
Transcription 
intermediary factor 1-
beta (TIF1-beta) 
2 1 
XPO2_HUMAN Exportin-2 (Exp2)  
0 1 
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Table 2.2. Thirteen proteins with “GG”-tag identified by mass spectrometry from 
cells overexpressing SUMO-1 (“GG-T95R”). Proteins were identified by nano-LC-
MS/MS from in-gel tryptic digestion followed by MASCOT search. T-complex protein 1 
subunit delta and Ran GTPase-activating protein 1 are also in the common protein list 
(Table 2.1). 
 
ADP-ribosylation factor 1 
Cell division cycle 2-related protein kinase 7 
C-jun-amino-terminal kinase-interacting protein 4 
EH-domain-containing protein 1 (Testilin) 
Endothelial zinc finger protein induced by tumor necrosis factor alpha (Zinc finger 
protein 71) 
Endothelin-1 precursor (Preproendothelin-1) (PPET1) 
Lethal(2) giant larvae protein homolog 1 (LLGL) 
Microtubule-associated protein 1B (MAP 1B) 
Protein Wnt-5b precursor 
Ran GTPase-activating protein 1 
Synaptonemal complex protein 1 (SCP-1) 
T-complex protein 1 subunit delta (TCP-1-delta) 
Tyrosine-protein kinase HCK 
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Chapter 3. The role of PDB-associated p62 mutants in NF-κB signaling pathway 
 
Introduction  
 
          PDB-associated p62 mutations are in 40% of the familiar PDB cases, and the 
upregulation (or defective) NF-κB signaling pathway is linked to PDB [7, 9]. Therefore, 
it is important to know the functional consequences of p62 PDB mutations [7, 9]. 
However, not much of the cellular impact of PDB-associated p62 mutations is known. In 
this Chapter, the focus is on the role of p62 PDB mutants in the NF-κB signaling pathway, 
which is related to the formation of hyperactivated osteoclasts as described in Chapter 1 
[59, 67]. Specifically, we ask two important questions: (1) Do PDB-associated p62 
mutations increase the NF-κB signaling? and (2) If so, by which mechanism do p62 PDB 
mutants increase the signaling?  
          Previous studies have reported that four mutations in p62 including P364S [79], 
K378X [81], P392L [79, 80] and E396X [81] increased NF-κB signaling. In this Chapter, 
whether several other mutants (M404V, G411S, D335E and A381V) also increase the 
NF-κB signaling was tested. Also, there is no report regarding how p62 PDB mutants 
increase the NF-κB signaling [9, 59]. Therefore, the possible mechanisms by which PDB-
associated p62 mutants increase the NF-κB signaling pathway were tested.  
          We initiated our study on the impact of p62 PDB mutants using Raw264.7 cells, 
which are osteoclast-like cells and widely used in the field [170]. To study the impact of 
PDB-associated p62 mutants on signaling, NF-κB luciferase assays and IκB degradation 
assays were performed in Raw264.7 cells overexpressing WT p62 and mutant p62 
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induced by the GST-rRANKL [171]. Due to the high background of endogenous p62 and 
low transfection efficiency of Raw264.7 cells, it was challenging to draw definite 
conclusions. TNFα and RANKL belong to the same family [172]. Therefore, we 
subsequently studied the impact of p62 PDB mutants in TNFα-induced NF-κB signaling 
using p62 KO MEF cells, which have the advantage of lacking of endogenous p62.          
  Furthermore, previous studies have reported that p62 facilitates TRAF6 
polyubiquitination, and activates the NF-κB signaling pathway [94]. Therefore, we firstly 
hypothesized that PDB-associated p62 mutants increase NF-κB signaling by increasing 
TRAF6 polyubiquitination. In this Chapter, we aim to test this hypothesis.    
 
Materials and methods 
 
Cells and reagents 
Raw264.7 cells were a gift from Dr. Lisa Cassis (University of Kentucky). WT 
MEF and p62 KO MEF cells were kindly provided by Dr. Masaaki Komatsu at Tokyo 
Metropolitan Institute of Medical Science [106]. The Raw264.7 cell line stably 
expressing the NF-κB luciferase reporter was generously shared by Dr. Jiake Xu 
(University of Western Australia, Australia) [170, 173]. HEK 293 cells stably expressing 
RANK receptor was kindly provided by Dr. Sarah Rea (Sir Charles Gairdner Hospital,  
Australia) and Dr. Julie Crockett (University of Aberdeen, United Kingdom) [79].  
Cells were cultured at 37°C with 5% CO2. HEK293 cells were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS), 100 units/ml penicillin and 100 µg/ml streptomycin. WT MEF and p62 KO 
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MEF cells were cultured in DMEM supplemented with FBS, PS, 100 mM  Sodium 
Pyruvate (11360-070; Invitrogen) and 10 mM  Non-Essential Amino Acids (11140-050; 
Invitrogen). Raw264.7 cells were cultured in  DMEM supplemented with FBS, PS, 
Sodium Pyruvate (Invitrogen), Non-Essential Amino Acids (Invitrogen) and 20 mM 
HEPES (15630-106; Invitrogen). For Raw264.7 cells stably expressing NF-κB luciferase 
reporter, an additional 400 µg/ml G418 (G8168; Sigma) was required. HEK293 cells 
stably expressing the RANK receptor were cultured in DMEM supplemented with FBS, 
PS and 100 µg/ml Hygromycin B (400053; EMD Biosciences).  
Additionally, GST-rRANKL, NF-κB luciferase reporter and HA-RANK plasmids 
were generous gifts from Dr. Jiake Xu (University of Western Australia, Australia) [171, 
173]. GST-rRANKL protein was purified with the help of Dr. Weimin Gong (Institute of 
Biophysics in Beijing, China). HA-Ub constructs including K29R, K48R and K63R were 
kindly shared by Dr. Marie Wooten (Auburn University). The 3xHA-Ub constructs 
including WT, “K48 only” and “K63 only” were gifts from Dr. Matthew Gentry 
(University of Kentucky). The phRL-TK (Renilla) vector used in this study was from 
Promega. The information of plasmids is summarized in Appendix I.  
 
Plasmid construction 
          The Myc-p62 (human) plasmid was a gift from Dr. Marie Wooten (Auburn 
University).  The human p62 was amplified by PCR and was inserted among the EcoRI 
and KpnI sites of the p3xFLAG-CMV10 vector (Sigma). Five PDB mutants, including 
D335E, A381V, P392L, M404V and G411S were generated by using the QuikChange II 
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Site-Directed Mutagenesis Kit (Stratagene). The details of these plasmids (Appendix I) 
and designed primers (Appendix II) for mutagenesis are shown in the Appendix.  
 
NF-κB luciferase assay  
For the study of RANKL-induced NF-κB signaling, 70% confluent Raw264.7 
cells stably expressing NF-κB luciferase reporter were transfected with Renilla control 
vector and WT p62 or p62 PDB mutants. Forty-eight hours after the transfection, cells 
were treated with GST-rRANKL (30ng/ml) for 7 hours. Cells were lysed with the Passive 
Lysis Buffer (PLB) of the Dual Luciferase Reporter Assay System (Promega). Aliquots 
of the cell lysates were subjected to SDS-PAGE and Western blotting using antibodies 
including anti-FLAG (A8592; Sigma) and anti-actin (sc-1616; Santa Cruz 
Biotechnology). The NF-κB luciferase assays were performed using the Dual Luciferase 
Reporter Assay System (Promega) using Optocomp I luminometer.  
For the study of TNFα-induced NF-κB signaling, 70% confluent p62 KO MEF 
cells or WT MEF cells were transfected with Renilla vector, NF-κB luciferase reporter 
and WT p62 or p62 PDB mutants. Twenty-four hours after the transfection, cells were 
starved with DMEM containing only 0.1% BSA for 4 hours. Cells were then treated with 
20 ng/ml mouse TNFα (315-01A; PeproTech, Inc.) overnight. The next day, cells were 
lysed in PLB. Aliquots of the cell lysates were subjected to SDS-PAGE and Western 
blotting using antibodies including anti-FLAG (A8592; Sigma) and anti-actin (sc-1616; 
Santa Cruz Biotechnology). NF-κB luciferase assays were performed using the Dual 
Luciferase Reporter Assay System (Promega).  
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Statistical analysis 
Three independent NF-κB luciferase assays in either p62 KO MEF cells or 
HEK293 cells were performed. All data were presented as mean with standard deviation 
(SD). The significant differences in NF-κB activity fold increases between control cells 
and cells expressing WT p62 were analyzed by t-test. The significant differences in NF-
κB activity fold increases among cells expressing WT p62 and p62 PDB mutant were 
analyzed by one-way ANOVA, with Tukey’s post-test using the software GraphPad 
Prism 5 Demo.  
 
Monitoring the rate of IκB degradation 
Raw264.7 cells or p62 KO MEF cells were transfected with WT p62 or M404V 
p62. After 24 hours, the cells were either left untreated or were treated with GST-
rRANKL (100 ng/ml) or mouse TNFα (30 ng/ml) for 15 or 45 minutes. Then, the cells 
were lysed with RIPA buffer (Millipore) supplemented with PMSF, P8340 protease 
inhibitor cocktail (Sigma), Na3VO4 and NEM for 30 minutes. The cell lysates were 
centrifuged at 1000g for 10 minutes and the supernatants were boiled with 6xSDS 
loading buffer. Samples were subjected to SDS-PAGE, followed by Western blotting 
using antibodies including anti-IκBα (mAb #4812; Cell Signaling) and anti-actin (sc-
1616; Santa Cruz Biotechnology).   
 
 
 
81 
P65 nuclear translocation  
Raw264.7 cells were left untreated or treated with GST-rRANKL (100 ng/ml) for 
30 minutes. The cells were fixed with 4% paraformaldehyde (PFA) at 37°C for 15 
minutes, permeabilized with 0.1% Triton in PBS and blocked with 3% bovine serum 
albumin (BSA) in PBS for 1 hour. All the primary and secondary antibodies were diluted 
in 3% BSA/PBS. Cells were first stained with p65 antibody (mouse, sc-8008, Santa Cruz 
Biotechnology, 1:50) overnight. The next day, the coverslips were washed with PBS and 
incubated with Hoechst  (33258; Sigma, 1:1000)  and secondary Alexa Fluor 488 anti-
mouse antibody (A21202; Invitrogen, 1:300) for 2 hours. Finally, the coverslips were 
mounted using Vectashield mounting medium (Vector Laboratories). Fluorescence 
microscopy was performed using a confocal microscope (Olympus FluoView) with a 60x 
objective.  
 
P62 siRNA 
          Raw264.7 cells or Raw264.7 cells stably expressing NF-κB luciferase reporter 
were transfected with non-targeting siRNA (Dharmacon, D-001210-01-05) or p62 siRNA 
(40nM or 80nM, Dharmacon, M-047628-01) using  Lipofectamine LTX transfection 
reagent (Invitrogen) in the Opti-MEM reduced serum medium (Invitrogen). Forty-eight 
hours after transfection, cells were lysed with RIPA buffer (Millipore). The cell lysates 
were centrifuged at 1000g for 10 minutes and the supernatants were boiled with 6xSDS 
loading buffer. Samples were subjected to SDS-PAGE. The knockdown efficiency was 
checked by Western blotting using antibodies including anti-p62 (H00008878-M01; 
Abnova) and anti-actin (sc-1616; Santa Cruz Biotechnology). 
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TRAF6 ubiquitination assay  
 
          HEK293 cells were transfected with FLAG-TRAF6 and DsRed-p62 (WT or 
mutant) using the Lipofectamine transfection reagent (Invitrogen). Forty-eight hours after 
transfection, cells were lysed using either PPHB buffer (50 mM Na2HPO4, 1 mM sodium 
pyrophosphate, 20 mM NaF, 2 mM EDTA, 2 mM EGTA and 1% Triton X-100) or RIPA 
buffer (Millipore). Cells were starved for 3.5 hours and treated with human TNFα 
(30ng/ml) for 10 minutes. The cell lysates were centrifuged at 1000g for 10 minutes and 
pre-cleared with Sepharose 4L-CB (Sigma) beads for 1 hour.  The lysates were then 
incubated with anti-FLAG M2 affinity beads for 2 hours at 4°C (F2426; Sigma). The 
beads were washed three times with lysis buffer and the immunoprecipitation (IP) 
products were eluted by boiling in SDS-PAGE loading buffer. The IP products and the 
extracts were subjected to SDS-PAGE using 4–20% ReadyGel Tris–HCl gradient gels 
(BioRad), followed by Western blotting with different antibodies including anti-ubiquitin 
(sc-8017, Santa Cruz Biotechnology), anti-FLAG (A8592; Sigma) and anti-actin (sc-
1616, Santa Cruz Biotechnology).  
 
Western blotting and quantification  
Nitrocellulose membrane was incubated in blocking solution, 5% milk in Tris-
Buffered Saline and Tween 20 (TBST) for one hour. Then the membranes were incubated 
with primary antibody for more than three hours. After four washes with TBST for five 
minutes each, the membrane was incubated with the secondary antibody for more than 
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one hour. After four washes again with TBST for five minutes each, proteins of interest 
were visualized by either normal or dura enhanced chemiluminescent (ECL) substrate 
(Thermo scientific) for detection of horseradish peroxidase (HRP) enzyme (Thermo 
scientific). The membrane was covered with the wrapping membrane and an 
autoradiography film (Denville Scientific) which was exposed to the membrane. The 
exposure time varied from one second to 20 minutes depending on the signal intensity. 
Films were subsequently developed by a Kodak X- OMAT 2000 processor.  
Software Image J was used for quantification of Western blotting bands on X-ray 
films. Since ECL signals of the Western blot were captured on X-ray films which are 
known to have a narrow linear range of detection, the quantification of the Western blot 
may be out of linear range for certain experiments. Enhanced chemofluorescence (ECF) 
substrate and Alkaline Phosphatase (AP)-conjugated secondary antibody are encouraged 
for use in the future.  
 
 
Results 
Effect of the p62 PDB mutation on RANKL-induced NF-κB signaling in Raw264.7 
cells 
 
          We used three classical techniques, including the NF-κB luciferase assay, IκB 
degradation assay and p65 nuclear translocation assay, to study the impact of PDB-
associated p62 mutants in the RANKL-induced NF-κB signaling.  
(1) NF-κB luciferase assay 
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          The schematic diagram of the NF-κB signaling in these studies is shown in Fig. 3.1. 
After RANKL treatment, a significant increase of the luciferase signal was observed, 
suggesting that the RANKL reagent and the whole system were working (Fig. 3.2 C). It 
was also shown that the endogenous level of p62 was high (Fig. 3.2 A). The level of 
overexpressed p62 was different among WT p62 and mutant p62 (M404V, A381V and 
P392L) (Fig. 3.2 A). Therefore, it is reasonable to normalize the NF-κB luciferase data 
using the expression level of p62 (Fig 3.2 B).  The original data of Firefly and Renilla 
were shown in Fig. 3.2 C. Fold increases after treatment were calculated by using the 
Firefly data divided by the Renilla. These increased ratios were further calibrated by 
using the data from the overexpressed p62 without treatment (Fig 3.2 B). Final calibrated 
fold increases were obtained (Fig. 3.2 D). It is shown that mutant M404V and A381V 
increased the NF-κB luciferase activity compared with WT p62 (Fig. 3.2 D). The high 
endogenous p62 level in Raw264.7 cells prevented us from further studying the impact of 
mutant p62 on signaling (Fig. 3.2 A). Also, the luciferase assay in HEK293 cells 
expressing the RANK receptor induced by RANKL was used, but did not produce a 
signal (data not shown). 
(2) IκB degradation assay 
           The IκB degradation assay in Raw264.7 cells induced by RANKL (Fig. 3.3) was 
then performed. When stimulated with RANKL, IκB was phosphorylated, ubiquitinated 
and degraded by the proteasome (Fig. 1.5). Therefore, the lower IκB level indicates 
increased NF-κB signaling activity. The data showed that the IκB level in cells 
expressing M404V was always lower than that in cells expressing WT p62 when treated 
with RANKL for either 15 or 45 minutes (Fig. 3.3 B). This result indicates that M404V 
 
 
85 
p62 increased the NF-κB signaling. Again, due to the high endogenous p62 level in 
Raw264.7 cells, it is difficult to reach a definite conclusion.  
(3) P65 nuclear translocation  
          Raw264.7 cells were either treated or untreated with RANKL for 30 minutes. P65 
nuclear translocation was observed using confocal microscopy. After stimulation of 
RANKL in Raw264.7 cells, a significant amount of p65 was observed in the nucleus (Fig. 
3.4 upper panel), whereas p65 remained in the cytoplasm without treatment (Fig. 3.4 
lower panel). These results indicate that RANKL induced p65 nuclear translocation. 
Since the high background of p62 is an issue, comparison of the WT p62 and mutant p62 
has not been done. Also, a better cell model system is needed to study the impact of p62 
PDB mutants in RANKL-induced NF-κB signaling (see “Discussion”).   
          Attempts to knockdown the endogenous level of p62 of Raw264.7 cells by using 
the siRNA were also tried. However, the p62 siRNA (40nM and 80nM) did not decrease 
the endogenous p62 level (Fig. 3.5). It is possible that Raw264.7 cells have low 
transfection efficiency for siRNA too.  
P62 contributes to TNFα-induced NF-κB signaling  
     
          Firstly, this study has shown that the Firefly/Renilla ratio after TNFα treatment was 
higher in WT MEF cells compared with p62 KO MEF cells (Fig. 3.6 A and B). It is 
shown that overexpression of WT p62 in p62 KO MEF cells increased the signaling 
compared with control p62 KO MEF cells (Fig. 3.6 C and D). Altogether, this suggests 
that p62 contributes to TNFα-induced NF-κB signaling. 
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          This conclusion is further supported by three independent TNFα-induced NF-κB 
luciferase assays in p62 KO MEF cells (Fig. 3.9 A). In order to find the best 
concentration of TNFα for measurement, cells were treated with different concentrations 
of TNFα (9 ng/ml, 18 ng/ml and 30 ng/ml) overnight. It is shown that 18 ng/ml 
performed best which could cause the largest difference of Firefly/Renilla signals 
between cells overexpressing WT p62 and control cells (Fig. 3.7). Therefore, 20ng/ml 
TNFα for the following luciferase assay for statistical study was used. It is shown that 
cells expressing WT p62 had higher fold increases  after TNFα treatment compared with 
control cells to a statistically significant extent, with the p value 0.034 (Fig 3.9 A).  
P62 PDB mutants have a tendency to increase NF-κB signaling compared with WT 
p62  
 
          Next, the impact of PDB-associated p62 mutants in TNFα-induced NF-κB 
signaling was examined. Firstly, it is shown that Firefly/Renilla signals were higher in 
p62 KO MEF cells overexpressing M404V p62 compared with WT p62, suggesting that 
M404V p62 increased  TNFα-induced NF-κB signaling compared with WT p62 (Fig. 3.6 
C and D).  Then, we performed three independent TNFα-induced NF-κB luciferase 
assays in p62 KO MEF cells (Fig. 3.8 and 3.9). The expression level of FLAG-p62 was 
similar among cells overexpressing WT and mutant p62 (Fig. 3.8 A). The expression 
level of p62 was also used for calibration of fold increases in the analysis (Fig. 3.9 C).  
          Firefly/Renilla signals with or without TNFα in cells overexpressing WT and 
mutant p62 are shown in Fig. 3.8 B. The fold increases were calculated by using 
Firefly/Renilla (with TNFα) divided by Firefly/Renilla (without TNFα). The luciferase 
data either without considering the p62 expression level (“Non-calibrated fold increases”, 
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Fig. 3.9 B) or considering the p62 level (“Calibrated fold increases”, Fig. 3.9 C) was 
analyzed. After statistical analysis, it is shown that p62 PDB mutants including M404V, 
A381V and P392L all increased signaling compared with WT p62 (Fig. 3.9 B and C).  
However, the increase is not statistically significant with the p value larger than 0.05.  
          The TNFα-induced NF-κB luciferase assay was also performed in HEK293 cells. 
The results have shown that p62 PDB mutants had a tendency to increase the signaling 
compared with WT p62 (Fig. 3.10 B).   
 
 
P62 PDB mutant suppresses its binding with polyubiquitinated proteins in HEK293 
cells 
 
          Next, we considered mechanisms by which p62 PDB mutants increased signaling.  
We started to study the cellular consequences of p62 PDB mutants. Because most of PDB 
mutations are in the UBA domain of p62, which binds the polyubiquitinated proteins [9], 
we want to know that whether these p62 PDB mutants have effects on the binding of 
polyubiquitinated proteins. 
          To address this question, HEK293 cells were transfected with human FLAG-p62 
(WT, M404V, A381V, P392L and G411S) or mouse p62 (WT and UBA domain deleted). 
Forty-eight hours after transfection, FLAG-IP was performed, and it was shown that all 
of the mutants, especially M404V and P392L p62, impaired the binding of p62 and 
polyubiquitinated proteins compared with WT p62 (Fig. 3.11). Mouse p62 (UBA domain 
deleted) also impaired its binding with polyubiquitinated proteins compared with mouse 
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WT p62, suggesting the validation of negative control (Fig. 3.11). However, for the 
FLAG-p62 IP shown in Fig. 3.11, whether it was polyubiquitination of p62 or 
polyubiquitination of other proteins remains investigation.  
 
Overexpression of p62 in HEK293 cells leads to TRAF6 polyubiquitination in 
HEK293 cells  
 
          As mentioned above, it was found that the p62 PDB mutations abolish binding with 
polyubiquitinated proteins in HEK293 cells. It has also been reported that TRAF6 
polyubiquitination is regulated by p62 [94]. Therefore, it is possible that p62 PDB 
mutations could have effects on TRAF6 polyubiquitination.  To address this question, the 
TRAF6 ubiquitination assay in HEK293 cells overexpressing FLAG-TRAF6 and DsRed-
p62 (WT, M404V, A381V and P392L) was performed.  
          It is shown that in the basal condition, the level of TRAF6 polyubiquitination in 
cells overexpressing WT p62 is much higher than control cells, indicating that 
overexpression of p62 in HEK293 cells leads to TRAF6 polyubiquitination (Fig. 3.12, 
3.13 and 3.14). In addition, it was found that the level of TRAF6 polyubiquitination 
increases in proportion to the amount of p62 (Fig. 3.13). It is indicated that the level of 
TRAF6 polyubiquitination is dependent on p62 amount.  
 
Mutant p62 impaired TRAF6 polyubiquitination compared with WT p62 in 
HEK293 cells 
 
          From the TRAF6 ubiquitination assay in HEK293 cells above,  it was shown that 
the level of TRAF6 polyubiquitination in cells overexpressing PDB-associated p62 
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mutants (M404V, A381V and P392L), especially M404V p62 is lower than cells 
overexpressing WT p62 (Fig. 3.12, 3.13 and 3.14). Therefore, p62 PDB mutants, 
especially M404V, impaired TRAF6 polyubiquitination compared with WT p62 in the 
basal condition. However, compared with control cells without overexpression  of p62, 
cells overexpressing p62 PDB mutant still increase TRAF6 polyubiquitination (Fig. 3.12, 
3.13 and 3.14), indicating that both the WT and the p62 PDB mutant could facilitate 
TRAF6 polyubiquitination in HEK293 cells.  
TNFα did not induce TRAF6 polyubiquitination in HEK293 cells  
 
          As mentioned above, it was shown that p62 contributes to TNFα-induced NF-κB 
signaling (Fig. 3.9 A). It was also shown that PDB-associated p62 mutants increased 
TNFα-induced NF-κB signaling (Fig. 3.9 and 3.10). Furthermore, it is shown that both 
WT and mutant p62 facilitate TRAF6 polyubiquitination in HEK293 cells in the basal 
condition (Fig. 3.12, 3.13 and 3.14). Therefore, it was of interest to determine whether 
WT p62 and p62 PDB mutants change TRAF6 polyubiquitination upon TNFα treatment 
compared with basal conditions. In order to address this question, TRAF6 ubiquitination 
assay was performed in the absence and presence of TNFα in HEK293 cells. It was 
shown that TNFα was effective because IκB was degraded after TNFα treatment (Fig 
3.14). However, the change of TRAF6 polyubiquitination after TNFα treatment (Fig. 
3.14) was not observed. Therefore, it is suggested TNFα does not play a role on TRAF6 
polyubiquitination in HEK293 cells.  
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Overexpression of p62 in HEK293 cells leads to a TRAF6 polyubiquitination chain 
of different linkages  
 
          Previous work has shown that p62 facilitates K63-linked polyubiquitination of 
TRAF6 and further activates the NF-κB signaling [95] (Fig. 1.5). In this study, it was 
found that p62 facilitates TRAF6 polyubiquitination in HEK293 cells. Therefore, is the 
TRAF6 polyubiquitination observed (Fig. 3.12 and Fig. 3.14) a K63-linked chain? Could 
the TRAF6 polyubiquitination observed activate the NF-κB signaling upon TNFα 
treatment? 
          To address these questions, HEK293 cells were transfected with FLAG-TRAF6, 
DsRed-p62 (WT) and a variety of different HA-Ub constructs including K29R, K48R, 
K63R [95], as well as “K48 only” or “K63 only”  in which all the Lys of Ub are mutated 
to Arg except Lys48 or Lys63, respectively. If it is a K63-linked chain, the level of 
TRAF6 polyubiquitination should decrease in cells overexpressing HA-Ub (K63R) 
compared with cells overexpressing WT Ub. However, this difference (Fig. 3.15, lane 1 
and 4) was not seen. There is no difference among levels of TRAF6 polyubiquitination in 
cells overexpressing K29R Ub, K48R Ub and K63R Ub (Fig. 3.15, lane 2-4). In addition, 
there is no difference between levels of TRAF6 polyubiquitination in cells 
overexpressing Ub (“K63 only”) and Ub (“K48 only”) (Fig. 3.15, lane 5 and 6).  
Altogether, it is suggested that the TRAF6 polyubiquitination observed is not a K63-
linked chain, but a mixture of K48-linked, K63-linked and K29-linked chains.  
          Moreover, from the TRAF6 polyubiquitination assay in HEK293 cells with and 
without TNFα treatment (Fig. 3.14), it is shown that overexpression of p62 could not 
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activate the NF-κB signaling because IκB level is similar in the absence and presence of 
p62 (Fig. 3.14). Therefore, the TRAF6 polyubiquitination observed by overexpressing 
p62 in HEK293 cells could not activate the NF-κB signaling (Fig. 3.14).  
 
Discussion  
Does p62 really facilitate TRAF6 to form a K63-linked polyubiquitin chain which 
activates NF-κB signaling? 
 
          Wooten et al. [95] and Moscat et al. [93] have shown that p62 could activate the 
NF-κB signaling in HEK293 cells in the basal condition. Our study not only showed that 
p62 activates NF-κB signaling basally (Fig. 3.6 C), but also upon TNFα treatment to a 
statistically significant degree in p62 KO MEF cells (Fig. 3.9 A) and HEK293 cells (Fig. 
3.10 A).  
          Wooten et al. [95] have reported that the loss of p62 completely abolishes 
ubiquitination of TRAF6 by performing TRAF6 immunoprecipitation from lysates of the 
brains from p62 WT or knock-out mice. In this study, it was shown that p62 facilitates 
TRAF6 polyubiquitination in HEK293 cells (Fig. 3.12 and 3.14). In their study, they have 
shown that the TRAF6 polyubiquitination chain is a K63-linked chain by using a variety 
of different Ub constructs. We also used these different Ub mutants and performed the 
TRAF6 ubiquitination assay as done previously [95]. However, it was found that the 
TRAF6 polyubiquitination chain is not K63-linked, but a mixture of K29-linked, K48-
linked and K63 linked. It was further confirmed by using two other different Ub mutants, 
“K48 only” and “K63 only”. The contradictory results between this study and Dr. 
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Wooten’s study might be due to the specific experiment details. In their study, although 
they have shown that TRAF6 polyubiquitination is a K63-linked chain, they did not show 
that this chain is sufficient to induce the NF-κB signaling. In this work, it was shown that 
the TRAF6 polyubiquitination observed is not sufficient to induce NF-κB signaling by 
comparing the IκB level in cells with and without overexpressing p62 (Fig. 3.14). 
          These data have shown that p62 contributes to NF-κB activation (Fig. 3.9 A). 
However, for the TRAF6 polyubiquitination assay, the IκB level remains similar in 
HEK293 cells with and without overexpressing p62, which seems to contradict that p62 
contributes to NF-κB signaling. To clarify this point in the future, more signaling proteins 
such as IKK and phospho-IκB need to be examined.  
 
Do p62 PDB mutants impair the TRAF6 polyubiquitination upon cytokine  
treatment? 
 
          In this Chapter, it was shown that M404V p62 impairs TRAF6 polyubiquitination 
compared with WT p62 in the basal condition (Fig. 3.12 and 3.14).  Also, it has been 
shown that M404V p62 had a tendency to increase TNFα-induced NF-κB signaling (Fig. 
3.10 B). Because TRAF6 polyubiquitination facilitates NF-κB signaling [125], these two 
pieces of data seem to be contradictory. However, it is suggested in the literature that, it 
is “K63 linked” polyubiquitination that facilitates NF-κB signaling. Was the “K63 
linked” polyubiquitination chain in our FLAG-TRAF6 IP observed? Actually it did not. 
These data have shown that the TRAF6 polyubiquitination chain is a mixture of 
polyubiquitination chains which contain K29 linked, K48 linked and K63 linked chains 
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(Fig. 3.15).  Therefore, overexpression of p62 could not facilitate TRAF6 to form the 
K63-linked chain.  
In addition, overexpression of p62 does not appear to activate NF-κB signaling 
because the IκB levels were similar in the absence and presence of p62 (Fig. 3.14). It is 
suggested that TRAF6 K63-linked polyubiquitination might require the stimulation of 
cytokines, such as TNFα or RANKL. It has also been shown that TNFα did not induce 
the TRAF6 polyubiquitination (Fig. 3.14). Therefore, it is indicated that TRAF6 K63-
linked polyubiquitination could be observed by stimulation with other cytokines, such as 
RANKL. 
Moreover, these data showed that TNFα did not increase TRAF6 
polyubiquitination (Fig. 3.14). Previous studies reported that TNFα increased TRAF2 
polyubiquitination [23, 93, 135], but they did not test whether TNFα increased TRAF6 
polyubiquitination. Thus, our study expands the knowledge of TNFα. In addition, 
Fuanakoshi-Tago et al. [174] have reported that TRAF6 negatively regulates TNFα- 
induced NF-κB signaling. They found that IKK activation and IκB degradation were 
enhanced in TRAF6-deficient MEFs compared with WT MEFs [174]. Although our data 
and their data are not directly related, all these studies showed at least that TNFα-induced 
NF-κB signaling is not activated through TRAF6.  
 
Three workable cell models for studying the impact of PDB-associated p62 mutants 
on NF-κB signaling 
 
(1) Raw264.7 cells 
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          Previously, Raw264.7 cells stably expressing the NF-κB luciferase reporter were 
used as a cell model to study the effect of the p62 on the RANKL-induced NF-κB 
signaling. It was thought that Raw cells constituted a good cell model because they are 
osteoclast-like cells [170], which are widely used in the field studying PDB. However, 
for this project, the goal was to examine the effect of PDB-associated p62 mutations on 
NF-κB signaling. Because all these p62 mutations are single point mutations, it was 
recognized that it is very important to rule out the effect of the endogenous p62 of Raw 
cells. It turned out that Raw cells have a high background of endogenous p62 (Fig. 3.2 A), 
whereas the transfection efficiency for Raw cells are also low. The use of p62 siRNA to 
knockdown the endogenous p62 of Raw cells was attempted, but p62 siRNA did not 
work; this might also be due to the low transfection efficiency of Raw cells (Fig. 3.5). 
Therefore, other cell models to study the signaling were considered.  
(2) p62 KO MEF cells  
          P62 KO MEF cells shared by Dr. Masaaki Komatsu (Japan) [106] were used for 
this study. The advantage of p62 KO MEF cells is that there is no endogenous p62 in this 
cell line. Therefore, it is advantageous to compare the effect of WT p62 and p62 PDB 
mutant using this p62 KO MEF cell line. The disadvantage of this cell line is that the 
transfection efficiency for the cell is also low. In addition, p62 KO MEF cells did not 
respond to the RANKL (data not shown). HA-RANK receptor (shared by Dr. Jiake Xu, 
Australia) was transfected into p62 KO MEF cells, and these cells again did not respond 
to RANKL (data not shown). However, p62 KO MEF cells did respond to TNFα (Fig. 
3.6). Therefore, the study shifted to the effect of PDB-associated p62 mutations on 
TNFα-induced NF-κB signaling. The TNFα-induced NF-κB luciferase assay was 
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performed in p62 KO MEF cells overexpressing either WT p62 or p62 PDB mutant for 
more than three times (Fig. 3.8 and 3.9). These data have shown a tendency for mutant 
p62 to increase TNFα-induced NF-κB signaling compared with WT p62, which is not 
statistically significant in p62 KO MEF cells. Additionally, it is shown that even without 
p62, there is still basal TNFα-induced NF-κB signaling (Fig. 3.9). Also, p62 increases the 
TNFα-induced NF-κB signaling pathway to a statistically significant degree (p<0.05) 
(Fig. 3.9 A). Therefore, p62 PDB mutants increase NF-κB signaling in p62 KO MEF 
cells, but the increase is so subtle that it is difficult to detect with NF-κB luciferase assay. 
(3) HEK293 cells  
          In addition, the TNFα-induced NF-κB assay in HEK293 cells was studied. 
HEK293 cells could also respond to TNFα signals (Fig. 3.10). In addition, the increased 
folds in cells expressing p62 (the number is over 50) are much higher than control cells, 
suggesting that it might be a good model to compare the effect of WT p62 and mutant 
p62 on TNFα-induced NF-κB signaling. 
   It appears to be challenging to study the RANKL-induced NF-κB signaling in this 
study. An ideal cell model should have little background of endogenous p62, high 
transfection efficiency and response after stimuli of RANKL. While it is difficult to find 
such a perfect cell model for study, some ways to optimize our existent cell lines are 
considered. The strategies are described below and summarized in Table 3.1.  
(1) HEK293 cells stably expressing RANK receptor 
Rea el al. [79] reported that P364S and P392L increased RANKL-induced NF-κB 
signaling by NF-κB luciferase assay in HEK293 cells stably expressing RANK receptor. 
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We also obtained the above stable HEK293 cells from them. Although we tried the same 
assay as described in their paper, the NF-κB signaling induced by GST-rRANKL [171] 
was not detected (data not shown).  
(2) p62 KO MEF cells stably expressing HA-RANK receptor 
HA-RANK receptor was also kindly shared by Dr. Jiake Xu (Australia). We also 
tried transient transfection of HA-RANK into p62 KO MEF cells, but again cells did not 
respond to GST-rRANKL [171] (data not shown). Because currently no report regarding 
using p62 KO MEF cells expressing HA-RANK receptor, there is a need to change the 
parameters for experiment optimization. If it works in the future, this approach might 
generate the p62 KO MEF cells stably expressing HA-RANK receptor.   
(3) Raw264.7 cells with p62 shRNA  
Since Raw264.7 cells have low transfection efficiency, lentivirus-delivered p62 
shRNA and exogenous p62 (WT or mutant) could be applied. It will be necessary to be 
careful about the design of p62 shRNA, which should only interfere with endogenous p62, 
not exogenous p62. Biosafety issues also need to be considered.  
 
Significance of this study and future directions 
            
          The significance of this study in this Chapter is that this is the first example using 
the p62 KO MEF cells as a model for studying the effect of p62 PDB mutants on NF-κB 
signaling. Also, this is the first study to show that p62 not only increases TNFα-induced 
NF-κB signaling basally, but also upon TNFα treatments in p62 KO MEF cells, which 
was not reported. Moreover, these data have shown that several PDB-associated p62 
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mutants had tendency to increase TNFα-induced NF-κB signaling, which was not 
reported before. Additionally, it excluded the possibility that these p62 PDB mutants 
increase signaling through increasing TRAF6 polyubiquitination, suggesting the 
existence of other mechanisms.  
 Future directions include examining other possible mechanisms by which p62 
PDB mutants increase TNFα-induced NF-κB signaling. Another direction is to find a 
better model to study the impact of PDB-associated p62 mutants on RANKL-induced 
NF-κB signaling (see Chapter 5). Additionally, previous studies have shown that p62 
interacts with RIP and is involved in the TRAF2 polyubiquitination [93] in the TNFα-
induced NF-κB signaling, which raises the possibility that PDB-associated p62 mutations 
increase TNFα-induced NF-κB signaling through increasing TRAF2 polyubiquitination. 
This hypothesis could be investigated in the future. 
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Figure 3.1. A schematic diagram of NF-κB luciferase assay. 
                                      
 
 
 
99 
 
Figure 3.2. RANKL-induced NF-κB luciferase assay in Raw264.7 cells expressing 
WT p62 and p62 PDB mutants.  Raw264.7 cells stably expressing NF-κB luciferase 
reporter were transfected with FLAG-p62 (WT, M404V, A381V and P392L) and Renilla. 
Forty-eight hours after transfection, cells were treated with GST-rRANKL (100ng/ml) for 
7 hours. Cells were harvested with passive lysis buffer and NF-κB luciferase assay was 
performed. Cell lysates were also subjected to SDS-PAGE and Western blotting was 
performed using antibodies against FLAG and actin. (A) Western blotting of 
overexpressed p62 and endogenous p62. (B) Quantification of FLAG-p62/Actin by 
Image J. (C) Original Firefly/Renilla ratio with or without RANKL treatment. (D) 
Normalized fold increases after RANKL treatment according to the expression level of 
p62.  
 
(A) 
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(B)                                                                                                                                                                           
              
  
(C)                                                                              (D) 
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Figure 3.3. Comparison of the rate of IκB degradation in Raw264.7 cells expressing 
WT and mutant p62 induced by GST-rRANKL. (A) IκB degradation in Raw264.7 
cells overexpressing WT or M404V p62 induced by RANKL at 10 or 45 minutes. (B) 
Quantification of IκB/Actin by Image J software.  
 
(A) 
 
 
(B) 
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Figure 3.4. Immunostaining of p65 in Raw264.7 cells induced by GST-rRANKL. 
Raw 264.7 cells were treated with and without GST-rRANKL (100ng/ml) for 30 minutes. 
Cells were fixed with 4% PFA and permeabilized with 0.1% Triton. Primary antibody 
p65 (1:50), secondary antibody Alexa Fluro 488 (mouse) (green, 1:300) and Hoechst 
(blue, 1:1000) were used. Confocal microscopy was applied for observation. Scale 
bars=5µm.  
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Figure 3.5. Knockdown of the endogenous p62 in Raw264.7 cells by p62 siRNA.  
Raw264.7 cells stably expressing NF-κB luciferase reporter were transfected with non-
targeting siRNA or p62 siRNA (40nM, 80nM) using the Lipofectamine LTX. Forty-eight 
hours after transfection, cells were lysed with RIPA buffer.  Samples were subjected to 
SDS-PAGE. The knockdown efficiency was checked by Western blotting using 
antibodies against p62 and actin. 
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Figure 3.6. TNFα-induced NF-κB luciferase assays in WT MEF and p62 KO MEF 
cells. (A) Firefly/Renilla ratio induced by TNFα in MEF cells. MEF cells were 
transfected with NF-κB luciferase reporter and Renilla. Cells were treated with TNFα 
(30ng/ml) for 7 hours. (B) Fold increases after TNFα treatment in p62 KO MEF and WT 
MEF cells. (C) Firefly/Renilla ratio at basal condition. MEF cells were transfected with 
FLAG-p62 (WT or M404V), NF-κB luciferase reporter and Renilla. (D) Firefly/Renilla 
ratio with or without TNFα treatment. Cells were treated with TNFα (30ng/ml) for 7 
hours. 
 (A) 
 
(B) 
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(C) 
                        
                     
(D) 
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Figure 3.7. NF-κB luciferase assay induced by different concentration of TNFα in 
p62 KO MEF cells.  (A) The Firefly/Rellina ratio was obtained at different concentration 
of TNFα (9ng/ml, 18ng/ml and 30ng/ml). The cells were starved with DMEM (0.1% 
BSA) for 4 hours, and then treated with TNFα overnight. (B) Fold increases by different 
concentration of TNFα.  
 (A) 
                           
   
 
(B)         
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Figure 3.8. TNFα-induced NF-κB luciferase assay in p62 KO MEF cells expressing 
WT p62 or p62 PDB mutants. P62 KO MEF cells were transfected with FLAG-p62  
(WT, M404V, A381V and P392L), NF-κB luciferase reporter and Renilla. Twenty-eight 
hours after transfection, cells were starved for 3.5 hours. Cells were treated with TNFα 
(20ng/ml) overnight. Cells were harvested with passive lysis buffer and NF-κB luciferase 
assay was performed. Cell lysates were also subjected to SDS-PAGE and Western 
blotting was performed using antibodies against FLAG and actin. Three independent 
experiments were performed. (A) Representative Western blotting of overexpressed p62 
and quantification of FLAG-p62/Actin by Image J. (B) Representative Firefly/Renilla 
with and without TNFα.  
 
 (A) 
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(B) 
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Figure 3.9. Statistical analysis of fold increases in the TNFα-induced NF-κB 
luciferase assay in p62 KO MEF cells. TNFα-induced NF-κB luciferase assay were 
performed three times. (A) Fold increases of Firefly/Renilla in control cells and cells 
expressing WT p62. The data were presented as mean ± S.D., and t-test was used to 
analyze the differences between the individual experiments. *: P < 0.05. (B) Fold 
increases of Firefly/Renilla in cells expressing WT p62 or p62 PDB mutant. The data 
were presented as mean ± S.D., and one way ANOVA analysis with Tukey’s test was used 
to analyze the differences between the individual experiments. (C) Fold increases of 
Firefly/Renilla in cells expressing WT p62 or p62 PDB mutant were calibrated according 
to the expression level of WT or mutant p62. The data were presented as mean ± S.D., 
and one way ANOVA analysis with Tukey’s test was used to analyze the differences 
between the individual experiments. 
 
(A) 
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(B) 
 
 
 
 
(C) 
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Figure 3.10. Statistical analysis of fold increases in the TNFα-induced NF-κB 
luciferase assay in HEK293 cells. TNFα-induced NF-κB luciferase assay were 
performed three times. HEK293 cells were transfected with FLAG-p62 (WT, M404V, 
A381V and P392L), NF-κB luciferase reporter and Renilla. Thirty hours after 
transfection, cells were starved overnight. Cells were treated with TNFα (30ng/ml) for 4 
hours. (A) Fold increases of Firefly/Renilla in control cells and cells expressing WT p62. 
The data were presented as mean ± S.D., and t-test was used to analyze the differences 
between the individual experiments. *: P < 0.05. (B) Fold increases of Firefly/Renilla in 
cells expressing WT p62 or p62 PDB mutant. The data were presented as mean ± S.D., 
and one way ANOVA analysis with Tukey’s test was used to analyze the differences 
between the individual experiments. *: P < 0.05. 
(A) 
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(B) 
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Figure 3.11. Comparison of immunoprecipitated polyubiquitinated proteins in 
HEK293 cells overexpressing WT and mutant p62. HEK293 cells were transfected 
with FLAG-TRAF6 (WT, A381V, P392L and M404V). Forty-eight hours after 
transfection, FLAG-IP was performed. Samples were subjected to 4–20% gradient gels. 
Western blotting was performed using antibody against Ub.  
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Figure 3.12. Comparison of TRAF6 polyubiquitination in HEK293 cells 
overexpressing WT and mutant p62. HEK293cells were co-transfected with FLAG-
TRAF6 and DsRed-p62 (WT, A381V, P392L or M404V). Forty-eight hours after 
transfection, FLAG-IP was performed. Samples were subjected to 4–20% gradient gels. 
Western blotting was performed using antibodies against Ub, FLAG and actin.  
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Figure 3.13. Comparison of the level of TRAF6 polyubiquitination in HEK293 cells 
overexpressing different amount of p62. HEK293 cells were co-transfected with 
FLAG-TRAF6 and different amounts (0.5µg, 0.25 µg and 0.1 µg) of DsRed-p62 (WT or 
M404V). Forty-eight hours after transfection, FLAG-IP was performed. Samples were 
subjected to 4–20% gradient gels. Western blotting was performed using antibodies 
against Ub and FLAG.  
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Figure 3.14. Comparison of TRAF6 polyubiquitination in HEK293 cells 
overexpressing WT and mutant p62 with and without TNFα treatment. HEK293 
cells were co-transfected with FLAG-TRAF6 and DsRed-p62 (WT, M404V, A381V or 
P392L). Forty-eight hours after transfection, FLAG-IP was performed. Samples were 
subjected to 4–20% gradient gels. Western blotting was performed using antibodies 
against Ub, FLAG, IκB and actin.  
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Figure 3.15. Comparison of TRAF6 polyubiquitination in HEK293 cells 
overexpressing p62 and a variety of different ubiquitin constructs. HEK293 cells 
were co-transfected with FLAG-TRAF6, DsRed-p62 (WT) and different HA-Ub 
constructs including K29R, K48R, K63R, K48 only and K63 only. Forty-eight hours after 
transfection, FLAG-IP was performed. Samples were subjected to 4–20% gradient gels. 
Western blotting was performed using antibodies against Ub, FLAG, DsRed and HA.  
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Table 3.1. Comparison of three workable cell models for our study. 
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Chapter 4. The role of PDB-associated p62 mutants in autophagy                                                
Introduction  
          It was reported that the p62 levels were elevated in PDB patients, suggesting a 
defect in autophagy [80, 175], which may play a role in the disease [7, 9]. Little is known, 
however, about the role of autophagy in PDB. As mentioned earlier, p62 mutations are 
linked to about 40% familiar PDB cases. Therefore, the effect of PDB-associated p62 
mutations in autophagy was investigated in our study.  
          There are two important questions regarding the role of p62 in PDB. (1) P62 is a 
regulator of autophagy [6, 90] , therefore do p62 PDB mutants increase or decrease 
autophagic activity compared with WT p62?  and (2) P62 is also a substrate of autophagy 
[82, 150], therefore does the rate of autophagic degradation of p62 PDB mutant increase 
or decrease compared with WT p62?   
          In this Chapter, we mainly try to address the first question. We compared the effect 
of WT p62 and p62 PDB mutants on the interaction of LC3, a marker for autophagosome. 
Then, we also compared the GFP-LC3 puncta among cells overexpressing WT p62 and 
mutant p62. In addition, we compared the LC3-II levels after rapamycin (autophagy 
inducer) and/or NH4Cl (autophagy inhibitor) treatment in cells expressing WT p62 and 
mutant p62.    
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Methods and materials  
 
Cells and reagents 
          P62 KO MEF cells were a gift from Dr. Masaaki Komatsu at Tokyo Metropolitan 
Institute of Medical Science [106]. Both rapamycin (autophagy inducer, R0395; Sigma) 
and NH4Cl (autophagy inhibitor, 254134-25G; Sigma) were used in this study.  
 
Plasmids construction 
          The human p62 open reading frame was amplified by PCR and was inserted among 
the EcoRI and KpnI sites of the p3xFLAG-CMV10 vector (Sigma). Five PDB mutants, 
including D335E, A381V, P392L, M404V and G411S were generated by site-directed 
mutagenesis (in Chapter 3). In addition, the FLAG-p62 (WT, A381V, P392L and 
M404V) was inserted between the EcoRI and KpnI sites of the pDsRed monomer C1, 
generating four human DsRed-p62 (WT, A381V, P392L and M404V). The mutagenic 
primer sequences of these DsRed-p62 constructs are listed in Appendix II.  
 
Immunoprecipitation  
          HEK293 cells were co-transfected with FLAG-p62 (WT, M404V, A381V and 
P392L) and EGFP-LC3 using the Lipofectamine reagent (Invitrogen). After 48 hours, the 
cells were lysed with the RIPA buffer with the PMSF (Sigma), P8340 (Sigma), Na3VO4 
and NEM for 30 minutes. The cell lysates were centrifuged at 1000g for 10 minutes. 
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Then 1000 μg cell lysates were pre-cleared with the Sepharose 4L-CB beads for 1 hour 
and subsequently incubated with anti-FLAG M2 affinity beads (F2426; Sigma). The 
beads were washed with RIPA buffer and resuspended in SDS loading buffer. The IP 
products and the extracts were subjected to SDS-PAGE followed by Western blotting 
with antibodies including anti-LC3 (PM036; MBL), anti-FLAG (A8592; Sigma) and 
anti-actin (sc-1616; Santa Cruz Biotechnology). 
 
Immunofluorescence and confocal microscopy  
P62 KO MEF cells were transfected with FLAG-p62 (WT or M404V) and EGFP-
LC3. Twenty-four hours after transfection, the cells were fixed with 4% 
paraformaldehyde (PFA) at 37 °C for 15 minutes, permeabilized with PBS/0.1% Triton, 
and blocked with 3% bovine serum albumin (BSA) in PBS for 1 hour. All the primary 
and secondary antibodies were diluted in 3% BSA/PBS. Cells were firstly incubated with 
anti-FLAG primary antibody (mouse, F3165; Sigma, 1:230) overnight. The next day, the 
cells on the coverslips were incubated with Hoechst  (33258; Sigma, 1:1000)  and Alexa 
Fluor 488 anti-mouse (A21202; Invitrogen, 1:300) for 2 hours. Finally, the coverslips 
were mounted using Vectashield mounting medium (Vector Laboratories). Confocal 
microscope (Olympus FluoView) was applied with a 60X objective.  
 
Fractionation   
P62 KO MEF cells were transfected with FLAG-p62 (WT or M404V) using the 
Lipofectamine LTX (Invitrogen). The cells were treated with NH4Cl (10mM, 16 hours) 
or rapamycin (200nM, 16 hours). Forty-eight hours after transfection, the cells were 
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harvested with RIPA buffer with PMSF (Sigma), P8340 (Sigma), Na3VO4 and NEM for 
30 minutes. The cell lysates were centrifuged at 1000g for 10minutes and the supernatant 
(S1) was collected. S1 was further centrifuged at 20,000g for 50 minutes, generating 
supernatant (S2) and pellet (P2). The samples were added to the 6xSDS loading buffer 
and subjected to the SDS-PAGE, followed by Western blotting using antibodies 
including anti-LC3 (PM036; MBL), anti-FLAG (A8592; Sigma) and anti-actin (sc-1616; 
Santa Cruz Biotechnology). 
 
Results 
Effect of the p62 PDB mutation on interaction with LC3 
 
          LC3-II is an active marker of the autophagosome [8], and p62 binds to LC3 
through the LIR domain of p62 [83]. The effect of PDB-associated p62 mutation on this 
interaction was tested in this study. HEK293 cells were co-transfected with FLAG-p62 
(WT, A381V, P392L and M404V) and EGFP-LC3. FLAG-IP was performed followed by 
SDS-PAGE and Western blotting. We used mouse LIR domain deleted p62 as a negative 
control, and as expected, it showed no interaction with GFP-LC3 (Fig. 4.1 A, lane 5). The 
p62 PDB mutation did not, however, change the interaction with LC3 (Fig. 4.1). The 
interaction of LC3 and p62 bearing a mutation (D335E) in LIR domain was also tested. 
Interestingly, this mutation also did not alter the interaction with LC3 (data not shown).  
 
Effect of the p62 PDB mutation on GFP-LC3 puncta formation  
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           In Chapter 3, we showed that M404V p62 impaired TRAF6 polyubiquitination 
compared with WT p62 in HEK293 cells (Fig. 3.12 and 3.14). Therefore, we chose this 
mutant for the study. P62 KO MEF cells were transfected with FLAG-p62 (WT or 
M404V) and EGFP-LC3. After 24 hours, the cells were fixed with 4% PFA and 
incubated with anti-FLAG antibody (1:230) and Hoechst (1:1000). Confocal microscopy 
was used to observe the GFP-LC3 puncta.   
          It was found that WT FLAG-p62 colocalized with GFP-LC3 (Fig. 4.2), which is 
consistent with reports in the literature [89]. The same colocalization was found for GFP-
LC3 and M404V p62 (Fig. 4.2). In addition, it was found that p62 and LC3 were 
exclusively located in the cytosol (Fig. 4.2). For quantification, nine Z-stack pictures for 
each sample were taken (data not shown). Attempts were made to count and compare the 
GFP-LC3 puncta in cells overexpressing WT and M404V p62 using available software. 
However, a larger number of cells and better software are needed for more precise 
quantification. 
 In the Fig. 4.2, it is shown that GFP-LC3 was in the nucleus. The nuclear staining 
of GFP-LC3 is likely due to high levels of overexpression. 
 
Effect of the p62 PDB mutant on LC3-II levels after rapamycin and NH4Cl 
treatment  
 
          In Chapter 1, I introduced several available autophagy inducers and inhibitors. 
Here, we used rapamycin, which inhibits the mTOR pathway, and activates autophagy. 
Also we used NH4Cl to inhibit the fusion of lysosomes and autophagosomes, thus 
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inhibiting autophagy (Fig. 1.7). The level of LC3-II was monitored after treatment with 
these compounds.  
          P62 KO MEF cells were transfected with FLAG-p62 (WT or M404V). Cells were 
then treated with rapamycin for 16 hours. Alternatively, cells were treated with 
rapamycin and NH4Cl together for 16 hours. Forty-eight hours after transfection, cells 
were lysed with RIPA buffer. Cell lysates were centrifuged at 1000g for 10 minutes. The 
supernatant (S1) was further centrifuged 20,000g for 50 minutes, generating supernatant 
(S2) and pellet (P2). The S1, S2 and P2 were subjected to SDS-PAGE followed by 
Western blotting.  
          Since rapamycin is an autophagy inducer, we expected to see LC3-II levels to 
increase after rapamycin treatment as more autophagosomes form. For cells without 
transfection (NT), LC3-II did increase slightly in S1 and S2, and decreased slightly in P2 
after rapamycin treatment (Fig. 4.3 A, lane 1 and 5). For cells transfected with empty 
vector or FLAG-p62 (WT or M404V), LC3-II remained similar in S1, and slightly 
decreased in S2 and P2 (Fig. 4.3 A, lane 2-4 and lane 6-8). Since LC3-II decreased in P2 
after rapamycin treatment in the control cells (Fig. 4.3 A, lane 2 and 6), it was indicated 
that rapamycin not only increased the formation of autophagosome, but also increased the 
enzymatic activity in the autophagolysosome, therefore more LC3-II was degraded.  
Based on Western blotting (Fig. 4.3 A), we quantified the LC3-II/Actin in S1 from cells 
overexpressing WT p62 or M404V p62 with and without rapamycin (Fig. 4.3 B). There 
was no significant difference between WT p62 and M404V p62 in terms of the change of 
LC3-II levels after rapamycin. LC3-II decreased after rapamycin in cells transfected with 
empty FLAG (Fig. 4.3 B), suggesting that rapamycin increased the enzymatic activity in 
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the autophagolysosome, thereby degrading LC3-II more rapidly. In cells overexpressing 
WT p62, the LC3-II levels decreased less compared with the control (7.9% vs. 23.2%) 
(Fig. 4.3 B), suggesting that WT p62 attenuated the autophagic activity and the rate of 
LC3-II degradation in the autophagolysosome. However, in cells overexpressing M404V 
p62, the LC3-II levels decreased more compared with cells overexpressing WT p62 
(18.3% vs. 7.9%), suggesting that PDB mutant p62 (M404V p62) may increase the 
autophagic activity compared with WT p62 because LC3-II was degraded at a faster rate.     
          NH4Cl decreases autophagy by inhibiting the fusion of lysosomes and 
autophagosomes. We expected, therefore, to see LC3-II levels increase after NH4Cl 
treatment. As expected, LC3-II increased dramatically in S1, S2 and P2 after NH4Cl 
treatment alone (data not shown). Rapamycin was applied with NH4Cl together with the 
expectation that this double treatment would raise LC3-II levels even further. Treatment 
with both compounds (Fig. 4.3 A, lane 9-12), however, did not further increase LC3-II, 
suggesting LC3-II reached maximal levels after treatment with NH4Cl alone (data not 
shown). Based on the Western blotting (Fig. 4.3 A), we quantified the LC3-II/Actin in S1 
from cells overexpressing WT p62 or M404V p62 with and without NH4Cl and 
rapamycin together (Fig. 4.3 C). It is shown that after double treatment, LC3-II levels in 
cells overexpressing WT p62 were higher than control (Fig. 4.3 C), suggesting that p62 
may facilitate the autophagic activity, which appears contradictory with Fig. 4.3 B. Also, 
it was shown that after double treatment, LC3-II levels in cells overexpressing M404V 
p62 were higher than those in cells overexpressing WT p62, suggesting that M404V p62 
may increase autophagic activity, which is consistent with Fig 4.3 B. However, since 
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LC3-II reached maximal capacity after treatment with NH4Cl, a solid conclusion 
regarding the impact of p62 PDB mutant on autophagy remains unclear.  
 
Discussion  
 
Challenges of current methods for studying the effect of PDB-associated p62 
mutants on autophagy 
 
          In this Chapter, we mainly used p62 KO MEF cells to study the effect of PDB-
associated mutants on autophagy. We used two common methods for the study. One is 
comparing the GFP-LC3 puncta in cells overexpressing WT or mutant p62, the other is 
comparing the LC3-II levels in cells overexpressing WT or mutant p62 after treatment 
with an autophagy inducer and/or inhibitor. 
          P62 KO MEF cells have the advantage of producing no endogenous p62. However, 
it is not an osteoclast-like cell. For quantitative study of GFP-LC3 puncta, since there will 
be a large number of cells and puncta for counting, a better program or software is 
needed to count the puncta using the same criteria for cells over-expresing WT or mutant 
p62.  
          Another challenge is that p62 is also a substrate of autophagy. Therefore it is a little 
complicated to explain the regulatory role of p62. There are two possibilities. If mutant 
p62 increases autophagic activity, the levels of the mutant p62 will decrease with time, 
self limiting the stimulation of autophagy. If mutant p62 decreases autophagic activity, 
the levels of the mutant p62 will accumulate through the time. Thus, autophagic activity 
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will continue to decrease with time. The second scenario might be the case, so the central 
hypothesis of our study would be: PDB-associated p62 mutants impair the autophagic 
activity, leading to accumulation of p62, which then further impairs the autophagic 
activity. Meanwhile, accumulated p62 mutants further increase the NF-κB signaling and 
the formation of osteoclasts, which leads to PDB (Fig. 5.1).   
 
Caution should be exercised when explaining LC3-II data 
 
          LC3-II is widely used to estimate autophagy activity [152]. However, we need to 
very carefully explain LC3-II data. When autophagic activities increase, LC3-II levels 
increase because more autophagosomes form. However, LC3-II itself is degraded by 
autophagy, the increased autophagic activity also lead to more degradation of LC3-II, 
therefore decreasing the LC3-II levels. Therefore, it is important to measure LC3-II in the 
presence and absence of lysosomal protease inhibitors (e.g. E64d and pepstatin A) or 
inhibitors which block the fusion of lysosomes and autophagosomes (e.g. NH4Cl and 
Bafilomycin A1). If mutant p62 really increases the autophagic activity, we will see LC3-
II levels increases after treatment of either lysosomal protease inhibitors or inhibitors 
blocking the formation of autophagolysosome in cells overexpressing mutant p62 
compared with cells overexpressing WT p62.  
          In our study, we used rapamycin as an inducer of autophagy and NH4Cl as an 
inhibitor. We expected to see LC3-II levels increase upon rapamycin treatment because 
more autophagosomes form. However, LC3-II decreased in P2 in the control cells after 
rapamycin treatment (Fig. 4.3 A, lane 2 and 6), suggesting that while rapamycin may 
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increase the formation of autophagosome, this may ultimately decrease LC3-II levels 
through increased degradation. In addition, cells treated with NH4Cl generated more 
LC3-II (Fig. 4.3 A, lane 9-12), suggesting that NH4Cl is a good inhibitor for blocking the 
fusion of lysosome and autophagosome.  Also, it seems that LC3-II reached maximal 
capacity after treatment with NH4Cl (Fig. 4.3 A, lane 9-12). In future, it is possible that 
using lower NH4Cl levels may allow useful measurements of changes in LC3-II levels.  
 
Significance of this study and future directions  
 
          In this Chapter, we examined the effect of PDB-associated p62 mutants on 
interaction with LC3, GFP-LC3 puncta formation and LC3-II levels upon autophagy 
inducer and/or inhibitor treatment. Our data have shown that p62 PDB mutants did not 
change interaction with LC3 compared with WT p62. In addition, we speculate that 
mutant p62 might impair autophagic activity, leading to the accumulation of p62. 
          For future studies, in order to better answer whether p62 PDB mutants change 
autophagic activity compared with WT p62, methods must be developed to quantify 
GFP-LC3 puncta.  Also, for the LC3-II study, other autophagy inducers (Beclin-1, 
starvation) and autophagy inhibitors (protease inhibitors E64d and pepstatin A) could be 
used. In addition, the question of whether autophagy change the rate of degradation of 
p62 PDB mutant compared with WT p62 has not been addressed.  In order to address this 
question, the half life of p62 could be monitored. 
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Figure 4.1. Comparison of the effect of WT p62 or PDB mutant p62 on the 
interaction of LC3. (A) HEK293 cells were transfected with FLAG-p62 (WT, A381V, 
P392L and M404V) and EGFP-LC3. FLAG-IP was performed, followed by the SDS-
PAGE. Western blotting was performed using the antibodies against the EGFP and 
FLAG. (B) Cell extracts of different samples.  
 
(A)                                                                       (B)           
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Figure 4.2. Immunostaining of p62 and LC3 in p62 KO MEF cells overexpressing 
p62 and GFP-LC3. P62 KO MEF cells were transfected with FLAG-p62 (WT or 
M404V) and EGFP-LC3. Twenty-four hours after transfection, cells were fixed with 4% 
PFA and permeabilized with 0.1% Triton. Primary antibody FLAG (1:230) and 
secondary antibody Hoechst (blue, 1:1000), Alexa Fluor 594 (mouse) (red, 1:300) were 
used. Confocal microscopy was applied for observation.  Scale bars=20µm. The nuclear 
staining of GFP-LC3 is likely due to high levels of overexpression. 
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Figure 4.3. Comparison of the effect of WT p62 and p62 PDB mutant on LC3-II 
level after rapamycin or rapamycin/NH4Cl treatment. (A) Western blotting of LC3-II 
in S1, S2 and P2 after fractionation in p62 KO MEF cells overexpressing WT or M404V 
p62. P62 KO MEF cells were transfected with FLAG-p62 (WT or M404V). The cells 
were treated with rapamycin (200nM) alone for 16 hours or NH4Cl (10mM) and 
rapamycin (200nM) together for 16 hours. Forty-eight hours post transfection, the cells 
were harvested with RIPA buffer. The cell lysates were fractionated into S1, S2 and P2. 
The samples were subjected to the SDS-PAGE, followed by Western blotting using the 
antibodies against the LC3, FLAG and actin. NT: non-transfection. (B) Quantification of 
LC3-II/Actin in S1 treated with rapamycin alone by Image J. The value of WT p62 is 
normalized to 100%. Percentage of decrease after rapamycin is shown in red. (C) 
Quantification of LC3-II/Actin in S1 treated with rapamycin/NH4Cl by Image J. The 
value of WT p62 is normalized to 100%. Percentage of increase after rapamycin/NH4Cl 
is shown in red.    
 
 (A) 
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Chapter 5. Discussion and future perspective 
 
Significance of this research  
 
          In Chapter 2, we introduced a relatively simple proteomic method to identify novel 
SUMOylation substrates. Seventy-four SUMOylated proteins were identified by our 
proteomic analysis (Table 2.1). Among these proteins, Ran GTPase-activating protein 1 
(RanGAP1) [12], proliferating cell nuclear antigen (PCNA) [169] and nucleophosmin 
(NPM) [168] have been reported to be SUMOylation substrates. In addition, 61 proteins 
have predicted SUMOylation sites and 40 proteins have SUMOylation consensus 
sequences (ΨKXE/D) (Table 2.1). Over 50% of these  proteins are nuclear proteins (Fig. 
2.4), which is consistent with literature that most SUMOylation substrates are in the 
nucleus [2]. Altogether, this suggests that our proteomic method is applicable for 
identification of SUMOylated substrates.  
 Moreover, we are the first group to identify a novel SUMOylation substrate 
called Drebrin, an actin-binding protein located in the cytosol [3, 45]. We verified 
Drebrin SUMOylation by both FLAG and HA immunoprecipitation (Fig. 2.8 A and B). 
Furthermore, by using site-directed mutagenesis, we found K185, K186, K270 and K271 
might be SUMOylation sites for Drebrin (Fig. 2.9 B). These lysines are conserved among 
vertebrate Drebrins by alignment of this region among different species (Fig. 2.7 C), 
suggesting that they are functionally important. At last, we observed the protrusion 
formation in CHO cells overexpressing Drebrin (WT and mutants) (Fig. 2.10 A), which is 
consistent with the literature [53, 54, 57]. However, mutation of these two sites 
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(K185R/K186R and K270R/K271R) in Drebrin separately did not appear to change 
protrusion formation (Fig. 2.10 B). 
Additionally, we also identified several nuclear proteins with multiple predicted 
SUMOylation sites (highlighted in Table 2.1), such as general transcription factor II-I, 
heterogeneous nuclear ribonucleoproteins C1/C2, nucleolin and 60S ribosomal protein 
L24. We could further validate SUMOylation of these proteins by IP and other methods 
in the future.   
In Chapters 3 and 4, our studies were related to “ubiquitination”, a similar 
modification of “SUMOylation”. We focused on an ubiquitin-binding protein, p62. We 
studied the effect of PDB-associated p62 mutants on NF-κB signaling and autophagy. In 
Chapter 3, we are the first group to use p62 KO MEF cells as a model for studying the 
effect of p62 PDB mutant on TNFα-induced NF-κB signaling. Wooten et al. [95] and 
Moscat et al. [93] have shown that p62 activated the NF-κB signaling in HEK293 cells 
basally. Our study not only showed that p62 activated NF-κB signaling basally (Fig. 3.6 
C), but also upon TNFα treatment in p62 KO MEF cells (Fig. 3.9 A) and HEK293 cells 
(Fig. 3.10 A).  In addition, we also have shown that p62 PDB mutants have a tendency to 
increase TNFα-induced NF-κB signaling compared with WT p62 in p62 KO MEF cells 
(Fig. 3.9 B and C) and HEK293 cells (Fig. 3.10 B). In addition, our data indicated that 
p62 did not increase TNFα-induced NF-κB signaling through increasing TRAF6 
polyubiquitination (Fig. 3.14), suggesting other mechanisms may exist (see below).  
 In Chapter 4, we studied the impact of PDB-associated p62 mutants on autophagy. 
We found that PDB mutations did not change the interaction between p62 and the 
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autophagy marker protein LC3 (Fig. 4.1 A). Whether p62 PDB mutants change the 
autophagic activity is not certain until we optimize our experiments by using autophagy 
inducer/inhibitor appropriately.  
In summary, my work has expanded our knowledge of the role of PDB-associated 
p62 mutants on NF-κB signaling and autophagy, as well as provided insights into several 
possible mechanisms, which are shown in an integrated model in Fig. 5.1. 
 
Functional consequences of SUMOylation of Drebrin and other proteins 
 
Although we detected SUMOylation of Drebrin, the modification does not appear 
to be involved in protrusion formation in CHO cells (Fig. 2.10 B). So what are the 
functional consequences of Drebrin SUMOylation? In Chapter 1, we introduced that 
SUMOylation modification of certain protein could bind other proteins only when 
SUMOylation is present. For example, only SUMOylated Ran-GAP1 binds RanBP2 [12]. 
Therefore, we hypothesized that Drebrin SUMOylation might also bind some proteins 
only when SUMOylation is present. So how to identify these target proteins which bind 
SUMOylated Drebrin, not non-SUMOylated Drebrin? We could take advantage of mass 
spectrometry to do the quantification for Drebrin interacting proteins from cells 
overexpressing WT Drebrin and mutant Drebrin. We will expect to see the amounts of 
some Drebrin interacting proteins are significantly higher in cells overexpressing WT 
Drebrin than Drebrin mutants, which impair Drebrin SUMOylation. These proteins are 
potential Drebrin interacting proteins only when Drebrin is SUMOylated. We will further 
verify their interaction by immunoprecipitation and Western blotting.  
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In addition, we could further validate the SUMOylation of proteins with higher 
predicted SUMOylation sites, which are highlighted in Table 2.1 by IP and other methods. 
We could also study the functional consequences of these proteins in the future.  
 
Mechanisms that PDB-associated p62 mutations increase NF-κB signaling  
 
In Chapter 3, we have shown that PDB-associated p62 mutations (M404V, 
A381V and P392L) had a tendency to increase TNFα-induced NF-κB signaling in p62 
KO MEF cells (Fig. 3.9) and HEK293 cells (Fig. 3.10). Previously, we hypothesized that 
p62 PDB mutant increased TNFα-induced NF-κB signaling through increasing TRAF6 
polyubiquitination. However, we showed that TNFα did not increase TRAF6 
polyubiquitination in HEK293 cells overexpressing WT and mutant p62 (Fig. 3.14), 
which did not support our hypothesis. Therefore, by what other mechanisms do p62 PDB 
mutants increase NF-κB signaling?  Several possibilities are described below and 
summarized in Fig. 5.1.  
(1) TRAFs or RIP polyubiquitination  
          Moscat et al. [93] showed that p62 could interact with RIP. They also showed that 
p62 interacted with TRAF2 in the presence of RIP by immunoprecipitation experiment in 
HEK293 cells transfected with p62, RIP and TRAF2 constructs. In their study, they also 
showed that upon TNFα treatment, p62 and RIP could be co-immunoprecipitated with 
TNF-R1. This suggested that the interaction of p62 and RIP plays a role in the TNFα-
induced NF-κB signaling. In Chapter 1, we also introduced that upon TNFα treatment, 
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TRAF2 undergoes auto-polyubiquitination (K63-linked), which catalyzes RIP K63-
linked polyubiquitination and activates the TNFα signaling [93] (Fig. 1.5). Our data 
showed that p62 contributed to TNFα-induced NF-κB signaling in p62 KO MEF cells 
(Fig. 3.9 A) and HEK293 cells (Fig. 3.10 A) by luciferase assay. Therefore, we 
hypothesize that WT p62 increases TNFα-induced NF-κB signaling by increasing 
TRAF2 or RIP polyubiquitination. Based on our data that p62 PDB mutants had a 
tendency to increase TNFα-induced NF-κB signaling (Fig. 3.9 and 3.10), we also 
hypothesize that p62 PDB mutant increases TNFα-induced NF-κB signaling by 
increasing TRAF2 or RIP polyubiquitination compared with WT p62.  
          In order to test our hypothesis, we should first set up a model system in which 
TRAF2 or RIP polyubiquitination increases upon TNFα, and the signaling proteins IKK 
increase, IκB decreases, phospho-IκB increases after TNFα treatment. Then, we will test 
whether TRAF2 or RIP polyubiquitination increases in the presence of p62. If so, we will 
have demonstrated that p62 involves in TRAF2 and RIP polyubiquitination. Next, we 
will compare the effect of WT p62 and p62 PDB mutant on TRAF2 and RIP 
polyubiquitination, see if mutant p62 could further increase polyubiquitination. If these 
experiments have results as expected, we could further examine TRAF2 or RIP 
polyubiquitination using a variety of different Ub constructs. If we find that TRAF2 or 
RIP polyubiquitination is a mixed linkage polyubiquitin chain, not a K63-linked 
polyubiquitin chain as we found for TRAF6 (Fig. 3.15), it will be a new finding to the 
field, that the mixed linkage polyubiquitin chain could also successfully activate the 
signaling. 
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 In addition, when the model for studying RANKL-induced NF-κB singnaling is 
available in the future, we could test whether PDB-associated p62 mutations increase 
RANKL-induced NF-κB signaling through increasing TRAF6 polyubiquitination.  
 (2) aPKC 
          In the NF-κB signaling pathway (Fig. 1.5), it is shown that p62 directly interacts 
with aPKC through its PB1 domain, and further activates IKK, leading to NF-κB 
activation. Therefore, we propose that PDB-associated p62 mutants increase the 
interaction with aPKC or increase the activity of aPKC compared with WT p62, and 
activate the signaling.  
          Duran et al. [77] demonstrated RANKL ligand-dependent interactions between p62 
and aPKC by immunoprecipitating endogenous p62 in Raw264.7 cells. However, they 
did not show negative controls in their IP. In our study, we performed the same 
experiment as they did, however our negative control was not working, since HA 
antibody could also pull down the endogenous aPKC in the absence and presence of 
RANKL (data not shown). Also, the IP efficiency is only about 13%.  In the long run, we 
could use better IP buffer or better HA antibody to improve the IP efficiency and 
diminish the effect of non-specific interaction. We could also use fusion protein p62 or 
aPKC (GST, GFP, Myc, FLAG, or DsRed tagged protein) to study the interaction. Once 
the experiment is set up, we could introduce WT p62 and p62 PDB mutants, and test if 
interactions with aPKC are changed. We could also monitor signaling proteins, such as 
IKK, IκB and phospho-IκB, and see if the activity of aPKC increases in the presence of 
mutant p62.  
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(3) CYLD  
          Jin et al. [176] reported that a deubiquitinating enzyme, CYLD, negatively 
regulates osteoclastogenesis and RANK signaling. They have shown that RANKL 
induced a much higher number of ostoclasts from the bone marrow-derived macrophages 
(BMDMs) in CYLD knockout mice than control mice. They also showed that 
ubiquitinated TRAF6 was accumulated in BMDMs from CYLD knockout mice. In 
addition, they showed that CYLD could interact with WT p62, but not UBA-deleted p62 
by IP, indicating that the interaction requires the UBA domain. Also, they showed that 
the interaction of CYLD and TRAF6 is dependent on p62 and its UBA domain by IP. 
          In light of their work, we hypothesized that p62 PDB UBA mutant decreases 
interaction with CYLD, leading to decreased deubiquitination of polyubiquitinated 
TRAF6, further increasing NF-κB signaling.  To test this hypothesis, HEK293 cells were 
transfected with human HA-CYLD [177] and human FLAG-p62 (WT and mutants) or 
mouse p62 (WT and UBA domain deleted). Forty-eight hours after transfection, FLAG-
p62 IP was performed. In contrast to Jin et al. [176], we found that CYLD co-
immunoprecipitated with mouse UBA-deleted p62 (data not shown).  In their study, they 
used the EGFP-p62, and we used FLAG-p62 in our study. In the future, to rule out non-
specific interactions, we could further change other tags (GST, GFP, Myc and DsRed), or 
use the human UBA-deleted p62, not mouse, as a better negative control.   
A recent study reported that the de-ubiquitination enzyme CYLD interacted with 
wild-type and a non-UBA mutant A381V p62 in osteoclast progenitor cells, but not to the 
UBA mutant P392L p62 [178]. Expression of p62 P392L also resulted in increased levels 
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of polyubiquitinated TRAF6 and phospho-IκB during osteoclast differentiation. These 
findings suggest that at least some p62 PDB mutations might perturb NF-κB signaling by 
altering CYLD activity and TRAF6 polyubiquitination.    
 
 (4) Other signaling proteins  
          Our data showed that p62 PDB mutants (M404V, P392L and G411S) suppressed 
its association with polyubiquitinated proteins (Fig. 3.11). Layfield et al. [116] also 
reported that p62 PDB mutants impaired K48-linked polyubiquitin binding in vitro. In 
Chapter 1, we introduced that p62 could bind polyubiquitinated proteins and target them 
for degradation by both UPS and autophagy (Fig. 1.6) [8]. Therefore, p62 PDB mutations 
may impair their binding with polyubiquitinated proteins that are active signal proteins in 
the NF-κB signaling pathway, leading to decreased protein degradation of these proteins, 
which might increase the NF-κB signaling. To test this hypothesis in the future, mass 
spectrometry could be applied for identification of these important targeting signaling 
proteins.  In detail, we could use mass spectrometry to do the quantification for the 
amount of proteins in cells overexpressing WT p62 and p62 PDB mutant (Fig. 3.11). We 
will expect to see that the amounts of some signaling proteins are significantly higher in 
cells overexpressing p62 PDB mutant than WT p62. These proteins could be candidate 
signaling proteins regulated by p62. When these certain proteins are polyubiquitinated, 
p62 PDB mutants fail to bind with these polyubiquitinated proteins, leading to less 
capable of sequestering these proteins for degradation. We would confirm these proteins 
by IP in cells overexpressing Ub and individual candidate proteins. In addition, p62 PDB 
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mutants could also impair autophagy activity leading to accumulation of important 
signaling proteins, and further activating NF-κB signaling (see below). 
 
Autophagy in PDB 
         
          In a recent autophagy review, it is suggested that autophagy may be related to the 
development of bone diseases, although the physiological roles of autophagy in bone are 
still mostly unknown [85]. In addition, the presence of inclusion bodies in osteoclasts 
seems to link PDB to autophagy [7]. Moreover, it is found that p62 colocalizes with 
Autophagy-Linked FYVE-domain containing protein (ALFY) in osteoclasts [7]. While 
this suggests that autophagy is linked to PDB [179], little is known about the role of 
autophagy in PDB so far. Therefore, the role of autophagy is clearly an area that merits 
investigation in the future. 
 Here, I offer some speculation of the role of autophagy based on the literature and 
our preliminary data in Chapter 4. P62 accumulation has been reported in French PDB 
patients with and without p62 mutations [175], suggesting that autophagy is impaired in 
PDB since p62 is a substrate for autophagy [147]. If impairment of autophagy is 
confirmed in a large number of PDB patients, what are the mechanisms? 
Defective autophagy in PDB patients could be related to PDB-associated p62 
mutants. As described in Chapter 1, p62 mutations are found in about 40% of familiar 
PDB [7]. Additionally, p62 is both a substrate and regulator of autophagy [8], therefore 
do PDB-associated p62 mutations contribute to the impairment of autophagy in PDB? In 
Chapter 4, we tried to use p62 KO MEF cells and several autophagy inducers and/or 
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inhibitors to test this hypothesis (Fig. 4.3).  In preliminary experiments with cells 
overexpressing WT p62, the LC3-II level decreased less than the control (7.90% vs. 
23.20%) after rapamycin treatment (Fig. 4.3 B), suggesting that overexpression of WT 
p62 attenuates the autophagic activity. Here, we propose that p62 PDB mutants could 
decrease the autophagic activity compared with WT p62, leading to accumulation of p62, 
which will further decrease the autophagic activity. In the future, this hypothesis could be 
tested by better experiment design, including better software to analyze the GFP-LC3 
puncta, more effective and appropriate usage of autophagy inducer and/or inhibitor and 
monitoring the endogenous and exogenous p62 levels as indicators of autophagy.  
          A recent review paper Goode et al. [9] suggests that defective autophagy and 
dysregulated NF-κB signaling in PDB may be linked. A number of signaling 
intermediaries of the RANKL-induced NF-κB signaling, such as IKK, are targets of 
ubiquitination [9, 62], which might be degraded by autophagy. Therefore, it would be 
interesting to determine the effect of PDB mutations on p62-mediated autophagic protein 
degradation of signaling intermediaries in the NF-κB signaling. In order to address this 
question, we could monitor the signaling proteins, including IKK, IκB and phospho-IκB, 
in cells treated with autophagy inhibitor/inducer in the absence and presence of RANK or 
TNFα.  
 Considering our findings of p62 PDB mutant on NF-κB signaling, a new 
proposed model showing that PDB-associated p62 mutants increase NF-κB signaling by 
several of the mechanisms is described in Fig. 5.1. P62 PDB mutants could also impair 
autophagy activity leading to accumulation of important signaling proteins, and further 
activating NF-κB signaling. Meanwhile, defective autophagy could lead to accumulation 
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of mutant p62, which would further impair autophagy and upregulate the NF-κB 
signaling, creating a feed-forward pathological cycle. This combined model is presented 
in Fig. 5.1.  
 
Other methods and models for studying the PDB 
 
          In Chapter 3, we compared cell models for studying the impact of PDB-associated 
p62 mutants on NF-κB signaling (Table 3.1). Among them, Raw264.7 cells might be the 
best one since they are osteoclast-like cells [170]. The main technique we used is the NF-
κB luciferase assay.  
           Aside from Raw264.7 cells and NF-κB luciferase assays, people used other 
methods and materials for studying PDB [80, 170].  Additional methods include bone 
resorption pit assay [80, 170], in vitro osteoclastogenesis assay [170], osteoclast 
apoptosis [80] and others. In addition, besides NF-κB luciferase assays, people used other 
methods to examine the NF-κB signaling. These methods include electrophoretic 
mobility shift assay (EMSA) [180, 181], nuclear:cytoplasmic ratios of NF-κB [182], 
monitoring the rate of IκB degradation [80] and p65 nuclear translocation [183]. In our 
study, we monitored the rate of IκB degradation (Fig. 3.3). However, our assay needs to 
be optimized by co-tranfection of HA-IκB (or other tags) with the FLAG-p62, in order to 
mornitor the IκB in cells expressing FLAG-p62 only. In addition, we also tried p65 
nuclear translocation in our study (Fig. 3.4). Again, we need to determine how to quantify 
p65 nuclear translocation between cells expressing WT p62 and mutant p62 in the future.  
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          Mouse models including mice expressing human P392L p62 [184] and P394L 
mutant mice [185] were reported previously. Isolated bone marrow macrophages (BMM) 
from WT and p62 mutant mice [170], isolated osteoclast precursors from healthy donors 
and PDB patients [184], cord blood monocyte (CBM) and peripheral blood mononuclear 
cells (PBMC) isolated from blood provided by healthy donors and PDB patients [80] 
were also applied in other people’s work.  
 Compared with our mutant p62 overexpressing in cells, using cells from PDB 
patient has its advantage of natural background of the PDB-associated p62 mutants. In 
the future, we may learn from these other methods and models.  
 
SUMOylation and NF-κB signaling 
 
          In Chapter 2, we mainly focused on identification of novel SUMOylation 
substrates. In Chapter 3, we investigated the PDB-associated p62 mutants in NF-κB 
signaling, which involves TRAFs polyubiquitination. The linkage of Chapter 2 and 
Chapter 3 seems to be that both SUMOylation and ubiquitination are important post-
translational modifications which also share similarities [2].  
          In addition, several signaling proteins in the NF-κB signaling pathway are reported 
to be SUMOylation substrates, such as TNF-R1 [35], IκB [30] and NF-κB essential 
modulator (NEMO) [186], the IKK regulatory subunit. Therefore, does SUMOylation 
play a role in the NF-κB signaling related to PDB? What is the interplay of SUMOylation 
and ubiquitination in the NF-κB signaling related to PDB? Could SUMOylation be 
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involved in the mechanisms of PDB? We could expand our knowledge of PDB by 
answering these questions.  
 
An integrated model: speculation about the role of PDB-associated p62 mutation 
 
In light of a recent review paper Goode et al. [9], as well as our work and the 
literature, I proposed a model integrating the role of PDB-associated p62 mutants on both 
NF-κB signaling and autophagy (Fig. 5.1). 
PDB-associated p62 mutants increase NF-κB signaling through several 
mechanisms including increasing aPKC activity, decreasing CYLD activity, increasing 
TRAF6/TRAF2 polyubiquitination, as well as increasing activity of unknown signaling 
proteins. Autophagy deficiency was detected in PDB patients, leading to the 
accumulation of mutant p62, which is proposed to further impair autophagy (dash line). 
P62 accelerates disease progression by upregulating NF-κB signaling through one or 
several of the mechanisms. Therefore, PDB-associated p62 mutants play a synergistic 
role in disease progression by affecting both NF-κB signaling and autophagy. The 
impairment of autophagy in PDB patient results in accumulation of mutant p62, which 
accelerates disease progression by increasing the NF-κB signaling. SUMOylation was 
found on several NF-κB signaling proteins including IκB [30], TNF-R1[35] and NEMO 
[186]. SUMOylation would therefore be involved in other mechanisms of PDB.  
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Figure 5.1. A proposed model for the role of PDB mutant p62 in NF-κB signaling 
and autophagy. PDB-associated p62 mutants increase NF-κB signaling through several 
mechanisms including increasing aPKC activity, decreasing CYLD activity, increasing 
TRAF6/TRAF2 polyubiquitination, as well as increasing activity of unknown signaling 
proteins. Autophagy deficiency was detected in PDB patients, leading to the 
accumulation of mutant p62, which is proposed to further impair autophagy (dash line). 
P62 accelerates disease progression by upregulating NF-κB signaling through several 
mechanisms. Therefore, PDB-associated p62 mutants play a synergistic role in disease 
progression by affecting both NF-κB signaling and autophagy. The impairment of 
autophagy in PDB patient results in accumulation of mutant p62, which accelerates 
disease progression by increasing the NF-κB signaling. In addition, SUMOylation would 
be involved in other mechanisms of PDB.  
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APPENDICES 
Appendix I: List of all constructs  
 
Plasmid Insert Vector Reference 
p3xFLAG-CMV10 N/A p3xFLAG-CMV10 Sigma 
pDsRedM = pDsRed-monomer 
C1 
N/A pDsRed-monomer 
C1 
Clontech 
p3xHA-CMV10 N/A The 3xFLAG tag 
of p3xFLAG-
CMV10 replaced 
with 3xHA tag  
Chapter 2, made by    
Dr. Jozsef Gal  
p3xFLAG-SUMO1(FL) N/A p3xFLAG-CMV10 Chapter 2 
p3xFLAG-SUMO1(GG)  p3xFLAG-CMV10 Chapter 2 
p3xFLAG-SUMO1(FL-T95R) T95R p3xFLAG-CMV10 Chapter 2 
p3xFLAG-SUMO1(GG-T95R)  p3xFLAG-CMV10 Chapter 2 
pDrebrin  pCMV Chapter 2                   
Dr. Tomas Brdicka 
[165] 
p3xHA-Drebrin  Human full-length, WT 
Drebrin 
p3xHA-CMV10 Chapter 2 
p3xHA-Drebrin,  K185R Human Drebrin K185R p3xHA-CMV10 Chapter 2 
p3xHA-Drebrin,  K186R Human Drebrin K186R p3xHA-CMV10 Chapter 2 
p3xHA-Drebrin,  K192R Human Drebrin K192R p3xHA-CMV10 Chapter 2 
p3xHA-Drebrin,  K270R Human Drebrin K270R p3xHA-CMV10 Chapter 2 
p3xHA-Drebrin,  K271R Human Drebrin K271R p3xHA-CMV10 Chapter 2 
p3xHA-Drebrin,  K185R/K186R Human Drebrin 
K185R/K186R 
p3xHA-CMV10 Chapter 2 
p3xHA-Drebrin,  K270R/K271R Human Drebrin 
K270R/K271R 
p3xHA-CMV10 Chapter 2 
    
   Contd. 
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p3xHA-Drebrin,  RRRRR Human Drebrin 
K185R/K186R/K192R/K270
R/K271R 
p3xHA-CMV10 Chapter 2 
pMYC-p62 (human) Human full-length, WT p62 pcDNA-MYC Dr. Marie Wooten 
p3xFLAG-p62 (human) Human full-length, WT p62 p3xFLAG-CMV10 Chapter 3, 4 and 5 
p3xFLAG-p62, D335E  Human p62 D335E p3xFLAG-CMV10 Chapter 3, 4 and 5 
p3xFLAG-p62, A381V  Human p62 A381V p3xFLAG-CMV10 Chapter 3, 4 and 5 
p3xFLAG-p62, P392L Human p62 P392L p3xFLAG-CMV10 Chapter 3, 4 and 5 
p3xFLAG-p62, M404V Human p62 M404V p3xFLAG-CMV10 Chapter 3, 4 and 5 
p3xFLAG-p62, G411S Human p62 G411S p3xFLAG-CMV10 Chapter 3, 4 and 5 
pDsRedM-p62 Human full-length, WT p62 pDsRed-
monomerC1 
Chapter 3, 4 and 5 
pDsRedM-p62, A381V Human p62 A381V pDsRed-
monomerC1 
Chapter 3, 4 and 5 
pDsRedM-p62, P392L Human p62 P392L pDsRed-
monomerC1 
Chapter 3, 4 and 5 
pDsRedM-p62, M404V  Human p62 M404V pDsRed-
monomerC1 
Chapter 3, 4 and 5 
p3xFLAG- p62 (mouse) WT, full-length mouse p62 p3xFLAG-CMV10 Chapter 3,made by    
Dr. Jozsef Gal [83] 
p3xFLAG- p62 (mouse), delta 
UBA 
Mouse p62, A2-T352 p3xFLAG-CMV10 Chapter 4, made by    
Dr. Jozsef Gal [83] 
p3xFLAG-TRAF6 Full-length, WT mouse 
TRAF6 
p3xFLAG-CMV10 Chapter 3 and 4      
Made by Dr. Jozsef Gal 
NF-κB luciferase reporter  pCMV Chapter 3 and 4,        
Dr. Jiake Xu [170, 
173].  
GST-rRANKL  pCMV  Chapter 3,                 
Dr. Jiake Xu [171]                    
phRL-TK   Promega 
p3xHA-Ub  p3xHA Chapter 3,                 
Dr. Matthew Gentry  
                Contd.  
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p3xHA-Ub, K48 only  K6R/ K11R/ K27R/ K29R/ 
K33R/ K63R 
p3xHA Chapter 3,                 
Dr. Matthew Gentry 
p3xHA-Ub, K63 only  K6R/K11R/ K27R/K29R/ 
K33R/K48R 
p3xHA Chapter 3,                 
Dr. Matthew Gentry 
pHA-Ub  pcDNA-HA Chapter 3,                  
Dr. Marie Wooten 
pHA-Ub, K29R K29R pcDNA-HA Chapter 3,                  
Dr. Marie Wooten 
pHA-Ub, K48R K48R pcDNA-HA Chapter 3,                  
Dr. Marie Wooten 
pHA-Ub, K63R K63R pcDNA-HA Chapter 3,                  
Dr. Marie Wooten 
pGFP-LC3 Mouse LC3B, P2-V125 pEGFP-C1 Chapter 5,               
Made by Dr. Jozsef Gal 
HA-CYLD Human full-length, WT 
CYLD 
pDEST-HA Addgene Plasmid 
15506 [177].  
 
 
 
150 
Appendix II: List of amplification primers and mutagenic primer sequences.  
 
Number Name Primer sequences 
GJ464 T375A reversion 
primer in the Wooten 
human p62 clone 
5’-CCTTCAGCCCTGTGGGTCCCTCCTG-3’ 
GJ465 T375A reversion 
primer in the Wooten 
human p62 clone 
5’-CAGGAGGGACCCACAGGGCTGAAGG-3’ 
GJ468 Human p62 upstream 
for N-terminal 
tagging (EcoRI) 
5’-GCTGGAATTCCGCGTCGCTCACCGTGAAG-3’ 
GJ469 Human p62 
downstream, cont. 
STOP (KpnI) 
5’-CGTCGGTACCTCACAACGGCGGGGGATG-3’ 
GJ470 Human p62 internal 
seq. primer 
5’-TGGTTGCCTTTTCCAGTGAC-3’ 
GJ471 Human p62 D335E 
QuikchangeII primer, 
upper strand 
5'-ACTGTTCAGGAGGAGAAGATGACTGGACCCATC-3' 
GJ472 Human p62 D335E 
QuikchangeII primer, 
lower strand 
5'-GATGGGTCCAGTCATCTTCTCCTCCTGAACAGT-3' 
GJ473 Human p62 A381V 
QuikchangeII primer, 
upper strand 
5'-GGCTGAAGGAAGCCGTCTTGTACCCACATCT-3' 
GJ474 Human p62 A381V 
QuikchangeII primer, 
lower strand 
5'-AGATGTGGGTACAAGACGGCTTCCTTCAGCC-3' 
GJ475 Human p62 P392L 
QuikchangeII primer, 
upper strand 
5'-CCAGAGGCTGACCTGCGGCTGATTGAG-3' 
GJ476 Human p62 P392L 
QuikchangeII primer, 
lower strand 
5'-CTCAATCAGCCGCAGGTCAGCCTCTGG-3' 
GJ477 Human p62 M404V 
QuikchangeII primer, 
upper strand 
5'-TCCCAGATGCTGTCCGTGGGCTTCTCTGATG-3' 
GJ478 Human p62 M404V 
QuikchangeII primer, 
lower strand 
5'-CATCAGAGAAGCCCACGGACAGCATCTGGGA-3' 
GJ479 Human p62 G411S 
QuikchangeII primer, 
upper strand 
5'-TCTCTGATGAAGGCAGCTGGCTCACCAGG-3' 
   
   
                                                                                             Contd. 
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GJ480 Human p62 G411S 
QuikchangeII primer, 
lower strand 
5'-CCTGGTGAGCCAGCTGCCTTCATCAGAGA-3' 
GJ757 hDrebrin Quikchange 
Multi, K185R 
K186R, upper strand 
5'-GTTCTGGGAGCAGGCCAGGAGGGAAGAAGAGCTGC-3' 
GJ758 hDrebrin Quikchange 
Multi, K185R 
K186R, lower strand 
5'-GCAGCTCTTCTTCCCTCCTGGCCTGCTCCCAGAAC-3' 
GJ759 hDrebrin Quikchange 
Multi, K192R, upper 
5'-AGAAGAGCTGCGGAGGGAGGAGGAGCG-3' 
GJ760 hDrebrin Quikchange 
Multi, K192R, lower 
strand 
5'-CGCTCCTCCTCCCTCCGCAGCTCTTCT-3' 
GJ761 hDrebrin Quikchange 
Multi, K270R 
K271R, upper strand 
5'-GAAGAGACCCACATGAGGAGGTCAGAGTCGGAGGTG-3' 
GJ762 hDrebrin Quikchange 
Multi, K270R 
K271R, lower strand 
5'-CACCTCCGACTCTGACCTCCTCATGTGGGTCTCTTC-3' 
GJ763 hDrebrin internal 
sequencing primer 
5’-AAGACGGATGCAGCTGTGGA-3’ 
GJ764 hDrebrin, upstream 
primer for p3xHA-
CMV10 (EcoRI) 
5’-CGTCGAATTCTGCCGGCGTCAGCTTCAG-3’ 
GJ765 hDrebrin, 
downstream primer 
for p3xHA-CMV10 
(BamHI) 
5’-CGTCGGATCCCTAATCACCACCCTCGAAGC-3’ 
GJ769 hDrebrin K185R 
Quikchange II, upper 
strand 
5'-CTGGGAGCAGGCCAGGAAGGAAGAAGAGC-3' 
GJ770 hDrebrin K185R 
Quikchange II, lower 
strand 
5'-GCTCTTCTTCCTTCCTGGCCTGCTCCCAG-3' 
GJ771 hDrebrin K186R 
Quikchange II, upper 
strand 
5'-TGGGAGCAGGCCAAGAGGGAAGAAGAGCTG-3' 
GJ772 hDrebrin K186R 
Quikchange II, lower 
5'-CAGCTCTTCTTCCCTCTTGGCCTGCTCCCA-3' 
GJ773 hDrebrin K270R 
Quikchange II, upper 
strand 
5'-GAAGAGACCCACATGAGGAAGTCAGAGTCGGAG-3' 
GJ774 hDrebrin K270R 
Quikchange II, lower 
strand  
5'-CTCCGACTCTGACTTCCTCATGTGGGTCTCTTC-3' 
GJ775 hDrebrin K271R 
Quikchange II, upper 
strand  
5'-GAGACCCACATGAAGAGGTCAGAGTCGGAGGTG-3' 
                                                                                                          Contd. 
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GJ776 hDrebrin K271R 
Quikchange II, lower 
strand  
5'-CACCTCCGACTCTGACCTCTTCATGTGGGTCTC-3' 
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Appendix III: List of abbreviations 
 
ALS: Amyotrophic lateral sclerosis  
aPKC: atypical protein kinase C 
CHO: Chinese hamster ovary  
Drebrin: Developmentally regulated brain protein 
EMSA: Electrophoretic mobility shift assay  
ERK: Extracellular responsive kinase 
FL: Full-length  
GFP: Green fluorescent protein 
HA: Hemagglutinin 
HEK: Human embryonic kidney  
HRP: Horseradish peroxidase  
hSUMO-1: human SUMO-1 
IKK: IκB kinase 
IκB: Inhibitor of NF-κB 
KO: Knockout  
LC3: Microtubule-associated protein light chain 3 
LIR: LC3 interaction region 
MEK5: MAPK/ERK kinase 5  
MEF: Mouse Fibroblast  
NBR1: Neighbor of BRCA1 gene 1 
NEMO: NF-κB essential modulator 
NF-κB: Nuclear factor κB 
NPC: Nuclear pore complex 
IP: Immunoprecipitation  
PDB: Paget’s disease of bone  
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PB1 domain: Phox and Bem1 domain 
PE: Phosphatidylethanolamine  
 
PML: Promyelocytic leukemia 
RANK: Receptor Activator of Nuclear Factor κB 
Ran-GAP1: Ran-GTPase-activating protein 1  
RIP: Receptor-interacting protein  
SDS-PAGE: Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SENP: Sentrin/SUMO-specific protease 
SUMO: Small Ubiquitin-like Modifier protein 
TB domain: TRAF6 binding domain  
TBST: Tris-Buffered Saline and Tween 20  
TNFα: Tumor Necrosis Factor-alpha 
TRADD: TNFR1-associated death domain protein 
 
TRAF6: TNF receptor associated factor 6 
TrkA:  Tropomyosin-receptor- kinase 
UBA domain: Ubiquitin-association domain  
UPS: Ubiquitin-proteasom system  
WT: Wild-type 
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